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Executive summary
Despite the long-standing political prominence of the problem, relatively coherent 
strategies and substantial investment, the United Kingdom remains at the top of the 
European ladder for drug use and drug dependence.  This study by Professor Peter 
Reuter of the University of Maryland, USA, and Alex Stevens of the University of 
Kent, England, assesses the evidence relating to the UK drug problem and analyses 
the impact of current policies.  
The nature of the drug problem
The United Kingdom has the highest level of dependent drug use and among 
the highest levels of recreational drug use in Europe.  The drug problem steadily 
worsened over the last quarter of the twentieth century: the number of dependent 
heroin users increased from around 5,000 in 1975 to a current estimated 281,000 in 
England and over 50,000 in Scotland.  Since the turn of the millennium, drug trends 
have shown signs of stabilisation, albeit at historically high levels.
About one quarter of those born between 1976 and 1980 have used a Class A drug at 
least once by 2005.  The percentage of young people who have used cannabis seems 
to have been decreasing in recent years, although it remains around 45%.  Use of 
other drugs that have been associated with youth cultures in the last few decades, 
including LSD, amphetamines and ecstasy, has also fallen, while cocaine use has 
increased.  But, most people use illegal drugs only for a short period of time.  
Occasional drug use is not the principal cause of Britain’s drug problems.  The bulk 
of drug-related harm (death, illness, crime and other social problems) occurs among 
the relatively small number of people that become dependent on Class A drugs, 
notably heroin and cocaine.
There were 1,644 identified drug-related deaths in the UK in 2005.  The UK has 
the second-highest rate of drug-related death in Europe, at about 34 per million 
population aged 16 or over.  The level of HIV among users in the UK is much lower 
than most other comparable European countries, with about 1.6% of injecting drug 
users being HIV positive.  However, 42% of injectors in England and 64% of injectors 
in Scotland are estimated to be infected with hepatitis C.
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Some of the estimated 327,000 problem drug users in England commit very high 
numbers of offences – most commonly shoplifting – to fund their drug use.  Around 
a fifth of arrestees appear to be dependent on heroin.  Illicit drugs may also be 
linked to violent crime through the direct effects of stimulants, such as crack 
cocaine, on aggression and through the operation of the illegal market, which is 
regulated by violence and fear.  It has recently been estimated that the size of the 
UK market for illicit drugs is over £5 billion, despite sustained reductions in drug 
prices.  The annual socio-economic cost of drug-related crime in England and Wales 
has been estimated at over £13 billion.  
Drug problems are disproportionately concentrated in areas of disadvantage.  
Problems such as drug dependency, drug-related deaths, infections, crime and 
mental illness cluster together in areas that are particularly socially deprived.
The policy response
Successive governments, initially across the UK and subsequently in the devolved 
administrations in Scotland, Northern Ireland and Wales as well have responded 
forcefully to this high-profile problem since the mid-1990s.  
The current 10-year UK Drug Strategy was initiated in 1998 and is therefore due for 
replacement or renewal in 2008.  It is wide-ranging and has included a number of 
targets that have changed over the years.  The current Public Service Agreement 
(PSA) targets for England were set in 2004.  They involve: 
•   reducing the harm caused by drugs, including health impacts and drug-related 
offending as measured by a Drug Harm Index, as well as increasing the number of 
drug-misusing offenders entering treatment through the Criminal Justice System; 
•   reducing frequent and Class A drug use by young people under 25, especially the 
most vulnerable; and
•   increasing the numbers of problem drug users in treatment by 100% by 2008 as 
well as increasing the proportion successfully sustaining or completing treatment.
In Scotland, Wales and Northern Ireland there are parallel strategies with broadly 
similar objectives.
To achieve these (and earlier) targets, the government and devolved administrations 
have sought to take action on a number of fronts, including:
•   a large and unparalleled increase in expenditure on treatment services;




•   increasing drug seizures and targeting ‘middle’ market drug dealers;
•   internationally, taking on principal responsibility for curbing heroin production in 
Afghanistan;
•   resisting calls to review the drug classification system but reclassifying cannabis 
from a Class B to a Class C controlled drug;
•   introducing information campaigns and increased coverage of drug education 
programmes in school;
•   early interventions with high risk groups such as truants and young offenders.
Despite the increased investment in treatment, the majority of government 
spending on responding to illegal drugs is still devoted to enforcing drug laws.  It 
is however difficult to estimate government expenditure on drug policy, as it is not 
transparently reported.  From the available data, we calculate that in the UK, as 
in other nations, enforcement expenditure (including police, courts and prisons) 
accounts for most of the total expenditure on drug policy.  
An assessment of subsequent impact
Drug use appears to have broadly stabilised in the UK since the turn of the 
millennium and in some cases there have been reductions in reported use, although 
cocaine and crack use has reportedly increased.  
The government has successfully increased the number of dependent drug users 
entering treatment, with enrolment in England increasing from 85,000 in 1998 to 
181,000 in 2004/5 with significant numbers of referrals through the Criminal Justice 
System.  Research suggests that this will have led to substantial reductions in drug 
use, crime and health problems at the individual level, with positive benefits for 
drug users, families and potential victims of crime.  The majority of this treatment 
involves the prescription of heroin substitution drugs (mostly methadone).  More 
than half of the estimated number of problem drug users are now in contact with 
structured treatment each year.  Waiting times have been cut sharply.
However, it is unlikely that the benefits of treatment to individuals and families 
will have translated into a substantial and measurable impact on overall levels 
of dependent drug use and crime at the national level.  International experience 
suggests that such impact is likely to be limited, due to the large numbers of 
users remaining untreated, the high rate of relapse, the variable effectiveness of 
treatment and the continual influx of new users.  
Harm reduction measures such as needle exchanges and methadone programmes 
appear to have successfully prevented a major HIV epidemic among injecting drug 
users in the UK compared to other countries.  However, they do not appear to have 
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prevented the rise of other blood-borne viruses such as hepatitis C.  
There is little international or UK evidence to suggest that drug education and 
prevention have had any significant impact on drug use.  The international literature 
consistently indicates that most school-based prevention efforts do little to reduce 
initiation.  Even those programmes that are delivered effectively seem to have very 
little impact on future drug use.
Despite fears that the reclassification of cannabis would lead to an increase in its 
use, cannabis use according to the most recent data has continued to decline since 
2001/2.
The use of custodial sentences for drug offenders increased substantially between 
1994 and 2005.  The annual number of people imprisoned rose by 111% and the 
average length of their sentences increased by 29%.  Taking into account the rise in 
the average sentence length (37 months for drug dealing in 2004), the courts handed 
out nearly three times as much prison time in 2004 as they did 10 years earlier.
Some enforcement measures around the street distribution of drugs can reduce the 
problems related to drug markets.  The impact of enforcement measures generally 
is experienced disproportionately amongst particular ethnic communities, notably 
black people who are arrested and imprisoned for drug offences at higher rates than 
white people.
Despite substantial increases in drug seizures, street drug prices have gone down, 
with the price for a gram of heroin falling from £70 in 2000 to £54 in 2005.  Tougher 
enforcement should theoretically make illegal drugs more expensive and harder to 
get.  The prices of the principal drugs in Britain have declined for most of the last ten 
years and there is no indication that tougher enforcement has succeeded in making 
drugs less accessible.
Policy implications
There is little evidence from the UK, or any other country, that drug policy influences 
either the number of drug users or the share of users who are dependent.  There are 
numerous other cultural and social factors that appear to be more important.  It is 
notable that two European countries that are often used as contrasting examples of 
tough or liberal drug policies, Sweden and the Netherlands, both have lower rates of 
overall and problematic drug use than the UK.
Given the international evidence as to the limited ability of drug policy to influence 
national trends in drug use and drug dependence, it is unreasonable to judge the 
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performance of a country’s drug policy by the levels of drug use in that country.  Yet 
that is the indictor to which the media and public instinctively turn.  However, this is 
not to say that drug policy is irrelevant.
 
The arena where government drug policy needs to focus further effort and where 
it can make an impact is in reducing the levels of drug-related harms (crime, 
death and disease and other associated problems) through the expansion of and 
innovation in treatment and harm reduction services.
We know very little about the effectiveness and impact of most enforcement efforts, 
whether they are directed at reducing the availability of drugs or at enforcing 
the law over possession and supply.  Imprisoning drug offenders for relatively 
substantial periods does not appear to represent a cost effective response.  
Transparency in resource allocations is urgently needed if the overall and relative 
balance of supply and demand reduction interventions is to be considered.
The UK invests remarkably little in independent evaluation of the impact of drug 
policies, especially enforcement.  This needs redressing if policy makers are to be 






UK policy on illicit drugs may change soon.  The drug strategy that was created in 
1998 is being reviewed in 2007/8.  The United Nations, which plays an important 
role in the international control system, will also evaluate how successfully the 
global community has fared in accomplishing the ambitions of the UN General 
Assembly Special Session of 1998, which called for a drug-free world.  The time is 
therefore right to examine the strengths and weaknesses of current UK policies.
This report will attempt to provide such an analysis.1  The report will focus on 
those psychoactive drugs that are currently categorised as illegal to import, sell 
and possess.  It will refer to tobacco or alcohol only as they interact with the other 
drugs, although we recognise that tobacco and alcohol are associated with more 
disease, violence 2 and mortality in Britain than all the illicit drugs combined.  We 
will endeavour to survey the diverse effects and problems that are associated with 
different kinds of drugs.  Different harms are associated with, for example, cannabis 
and heroin, and different responses are therefore appropriate.
By policy, we mean the pattern of legislation and government action that aims to 
affect the use of drugs and the related problems.  The remainder of this chapter 
describes very briefly the evolution of drug legislation.  Chapter 2 examines the 
population pattern of use of the various illicit drugs, in particular how they have 
changed over time.  Chapter 3 discusses the harms that are associated with these 
patterns of use, focusing on the most severely affected groups.  This will provide 
the basis for the discussion, in Chapter 4, of current policies and their effects.  The 
report will conclude, in Chapter 5, with brief assessments of the limits of drug policy 
and the effectiveness of current British policy.  
Legislation
The Misuse of Drugs Act 1971 (MDA) continued a process of increasing legal control 
of psychoactive substances in the twentieth century (see ‘A brief history of drug 
control legislation’, page 15).  This has passed through four distinct phases.  Until 
1916, there was very little legal control of drug use.  Various preparations derived 
from opium and coca were available for sale, and were widely used.  Mounting 
concern over the use of cocaine and other drugs by troops on leave during World 
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War I (Spear and Mott 1993), and then by young white women and ‘men of colour’ 
in the London underworld (Kohn 2001) accompanied the second phase of control, 
between 1916 and 1928.  Criminalisation of the distribution and use of cocaine and 
mainly morphine (and later cannabis) were combined with the availability of cocaine 
and heroin to addicts through doctors, an arrangement that came to be known as 
the ‘British system’ and was confirmed by the Rolleston committee of 1926.  This 
system separated the treatment of dependent drug users from the punishment of 
unregulated use and supply.  Until the 1960s, British policy on drugs followed this 
system, which was found nowhere else.  The number of users was never large and 
prevalence of drug use remained low, while small numbers of dependent users 
continued to receive prescribed drugs from doctors as part of their treatment.  
In the 1960s, two events generated a sharp increase in the level of legal control 
of illicit drugs.  The first was the prescription of large amounts of heroin by a 
few doctors, which led to diversion into the illegal market.  The second was the 
increasing use of substances such as cannabis, amphetamines and LSD that had 
not previously existed to a very great extent in the UK.  This led to the third phase of 
British drug policy, when increasing control accompanied rising prevalence between 
the 1960s and 1980s.  By the early 1970s methadone overtook heroin as the main 
drug for heroin addicts in treatment, though properly licensed physicians retained 
the right to prescribe heroin (see Strang and Sheridan 2006).  The MDA brought 
together the various measures that had been introduced in previous legislation 
and introduced the three-tier classification framework by which drugs are still 
classified.  In the 1980s, as concern mounted over increasing heroin use, penalties 
for trafficking and supply were increased.  
In 1991, the first legal attempt to integrate health and criminal justice responses, in 
the form of Schedule 1A6 Probation Orders, ushered in the fourth and most recent 
phase of drug legislation.  There is now less of the separation between medical and 
punitive responses that had characterised the British system in the past.
British drug legislation should not be considered without acknowledging the 
influence of international agreements and conventions, which have been largely 
driven by the USA.  Mott and Bean (1998) have argued that the main legal 
innovations between 1925 and 1964 were in response to international pressures, not 
domestic problems.  The United Nations conventions still impose limits on national 
drug legislations, which are still most powerfully upheld by the USA (Transnational 
Institute 2005).3  
Overall, both international and British legal developments show a punctuated 
but inexorable increase in the level of legal control of drugs.  As will be shown in 
Chapter 2, these laws have not succeeded in their primary aim of reducing the 
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prevalence of use of the targeted drugs.  The UK now has the highest rates of illicit 
drug use in the European Union and over 10 million people in England and Wales are 
estimated to have used illicit drugs (Roe 2005).
Table 1.1 shows how controlled drugs are currently classified .  Classes A, B and C 
are used to categorise drugs according to the perceived danger they pose to users 
and society, with penalties set higher for the more dangerous drugs.  The current 
debate over these classifications will be examined in Chapter 4.  Box 1.1 provides a 
summary of the historical development of British drug legislation.






























Box 1.1  A brief history of drug control legislation
Introducing legal controls
1868 – Pharmacy Act.  First regulation of poisons and dangerous substances, 
limiting sales to chemists.  
1908 – Poisons and Pharmacy Act.  Specifically included coca in regulations on 
sale and labelling.
Creating a national system
1916 – Defence of the Realm Act, 1914 (Regulation 40B).  Restricted sales and 
possession of cocaine to ‘authorised persons’.
1920 – Dangerous Drugs Act.  Limited production, import, export, possession, 
sale or distribution of opium, cocaine, morphine or heroin to licensed persons.
1925 – Dangerous Drugs Act.  Introduced control of the importation of coca leaf 
and cannabis.
1928 – Amendment to Dangerous Drugs Act to criminalise possession of cannabis  
(but doctors able to prescribe any drugs as treatments for general medicine or for 
addictions).
Increasing control
1964 – Dangerous Drugs Act.  Ratified UN 1961 Single Convention and 
criminalised cultivation of cannabis. 
Drugs (Prevention of Misuse Act) criminalised the possession of amphetamines.
1967 – Dangerous Drugs Act.  Required doctors to notify Home Office of addicted 
patients.  Prescription of heroin and cocaine for treatment of addictions 
restricted.
1971 – Misuse of Drugs Act.  Set up the system classifying drugs according to 
their perceived harmfulness.  Created offence of ‘intent to supply’ and set harsher 
penalties for trafficking and supply.  Established The Advisory Council on the 
Misuse of Drugs (ACMD).
1985 – Controlled Drugs (Penalties) Act.  Increased maximum penalty for 
trafficking Class A drugs from 14 years to life imprisonment.
Introduction
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1986 – Drug Trafficking Offences Act.  Created an offence of making suspects 
aware of an investigation.  Empowered police to compel breaches of 
confidentiality and to search and seize material and assets.
Integrating criminal justice and health
1991 – Criminal Justice Act.  Schedule 1A6 allowed for the condition of attending 
drug treatment to be attached to a probation order.
1998 – Crime and Disorder Act.  Created the Drug Treatment and Testing Order 
(DTTO).
2000 – Criminal Justice and Court Services Act.  Enabled police to drug test 
people charged with ‘trigger’ offences.  Created the Drug Abstinence Order, the 
Drug Abstinence Requirement and testing for supervised, released prisoners.
2003 – Criminal Justice Act.  Enabled restrictions on bail for some arrestees 
(‘trigger offences’) who test positive for Class A drug use.  Created the generic 
Community Order, replacing the DTTO with the Drug Rehabilitation Requirement.
Anti-Social Behaviour Act.  Powers to close premises used for Class A drugs 
supply.
2005 – Drugs Act.  Introduced drug testing on arrest.  Criminalised possession 
and sale of unprocessed psilocybin mushrooms.  Made it illegal to refuse a 
required treatment assessment.  Increased penalties for dealing near schools.
2006 – Police and Justice Act.  Extends the conditional cautioning scheme to 




Drug use in Britain
It is difficult to estimate the number of persons who use illegal drugs in the UK,  
and extremely difficult to estimate the total quantity that they consume.  Recent 
years have seen the development of regularly administered surveys, such as the 
British Crime Survey (BCS) and its Scottish parallel, and various studies of school 
pupils, which ask respondents to report their drug use.  Respondents are promised 
confidentiality.  Given that nearly half report some use of illegal drugs, clearly many 
respondents are willing to report that they have violated the law by possessing 
drugs.  However some almost certainly do not and there is an almost irresolvable 
controversy about the extent of under-reporting.1  Unfortunately, there are no 
indirect indicators that provide an alternative method for estimation of the total 
numbers of users.
Another barrier to the accuracy of survey estimates is that household and school 
surveys are likely to miss those people who are amongst the heaviest users of illicit 
drugs: the homeless, prisoners and school truants.  Dependent users of cocaine 
and heroin may also be of unstable residence, and less likely to be found in their 
residence at a given time.  Estimates of young peoples’ drug use from the BCS are 
also affected, almost certainly in the direction of underestimating prevalence and 
frequency of drug use, by the exclusion of students who live in university halls 
of residence.  What the surveys are good for is the assessment of trends in the 
occasional use of drugs other than cocaine and heroin.  
The surveys are not good for estimating the number of dependent users of 
expensive and addictive illicit drugs.   BCS estimates of the prevalence of the use 
of the most problematic drugs, including heroin and crack, appear implausibly low.  
Extrapolation from the 2001 BCS provided an estimate that there were fewer heroin 
users than had actually presented to treatment for heroin problems in that year 
(Hickman et al.  2004).  A capture–recapture study in London found rates of crack 
use that were four times higher than had been found in population surveys (Hope et 
al. 2005).
More sophisticated studies aimed at estimating the extent of ‘problematic drug use’ 
have been developed, using a variety of data sources, and better indicator systems 
are being developed.  We judge that there are moderately credible estimates of the 
18
extent of dependent heroin and cocaine use in the UK.  The latest estimate is that 
there were 327,000 problematic drug users in England 2004/5 (Hay et al. 2006).2  
The available estimates for other UK countries are older, relating to 2000, when 
it was estimated that there were approximately 55,800 problematic drug users in 
Scotland, 800 in Northern Ireland and 8,000 ‘serious drug users’ in Wales (Eaton et 
al. 2005).  
The available data will be examined in more detail in this chapter and in Chapter 4, 
where we argue that the limitations of current indicators have serious implications 
for targeting, accountability and performance management in current UK drug 
policy.  
Drug use is a common experience for those born in the United Kingdom since at 
least 1970.  However, the majority of those who try an illegal drug use cannabis 
only a few times and do not go on to use other drugs or experience much harm.  A 
small minority do go on to become dependent and troubled users of heroin and 
cocaine.  These people tend to use drugs very frequently and so they contributed 
disproportionately to the estimated £5.3 billion spent on illicit drugs in the UK in 
2003/4 (Pudney et al.  2006).  
This chapter begins with a description of the trends in drug use in the general 
population and then moves to a more detailed description of patterns of use of the 
two most problematic drugs, heroin and cocaine.  It concludes by comparing UK 
drug use with that in other similar nations.
Drug use in the general population
It now seems that what might be termed ‘recreational’ drug use has become firmly 
established as an experience that many young people will go through.  One broad 
measure of that is the percentage of various birth cohorts who have tried an illegal 
drug at least once.  In Table 2.1, we present data on England and Wales from the 
2005 British Crime Survey (Roe and Man 2006) on the percentage of persons of 
different ages that have used at least one illicit drug at least once.  We see that for 
those born between 1961 and 1970 (aged 35–44 in 2005), about one-third had used 
some drug but that for those born between 1971 and 1975 (aged 30–34 in 2005) the 
figure had risen to over 45% and is over 50% for those born between 1976 and 1980 
(aged 25–29 in 2005).  
The largest fraction have used cannabis – over 40% for those born since 1975.3  The 
proportions that have experimented with more serious drugs (Class A), though 
smaller, are still substantial.  For those born between 1976 and 1980, over one-
quarter reported at least one use of a Class A drug, with nearly one in six reporting 
Drug use in Britain
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use of cocaine.  As noted earlier, it is useful to remember that these are probably 
underestimates of the true proportions.
However, the percentage of people who use these drugs regularly over long periods 
of time is very much smaller.  Table 2.2 provides data on last year use rates for the 
same age groups and drugs presented in Table 2.1.  Whereas 26.5% of 25- to 29-year-
olds reported ever having used a Class A drug, only 6.9% reported that they had used 
such a drug in the past year.  Even for cannabis, only about one-third of the 25- to 
29-year-olds reporting ever having used the drug reported that they had used it in the 
previous year.  Most people who use illicit drugs only do so for a short time.  
Last year use of drugs in Scotland shows a similar pattern, with use peaking in 
the 20–24 age group.  In this group, the estimated proportions of people using 
cannabis, cocaine, ecstasy and opiates in 2004 were 25.3%, 5.6%, 5.9% and 1.5% 
respectively (Murray and Harkins 2006).  
There are variations in reported drug use between sexes and ethnic groups.  In 
the British Crime Survey, 40.6% of men reported having ever used an illicit drug 
compared to 29.4% of women.  This pattern of higher drug use among men holds 
true across age groups, for different drugs and for lifetime and past year use (Roe 
and Man 2006), although the difference between the sexes’ drug use patterns do 
seem smaller among school pupils (NatCen/NFER 2006) than those aged over 16.  
Table 2.1  Figures for the proportion of 16- to 59-year-olds reporting having used 




















Cannabis 35.1 44.4 46.7 40.1 28.5 18.8 11.1 29.8
Amphetamines 7.5 14.5 23.8 20.5 11.8 5.6 2.8 11.5
Any cocaine 6.5 14.5 15.2 10.4 6.4 2.4 1.1 7.3
Ecstasy 5.8 14.4 18.2 14.0 5.7 0.9 0.2 7.2
Opiates 0.4 1.1 1.9 1.2 0.9 0.5 0.3 0.9
Class A 11.2 21.8 26.5 21.4 13.6 6.6 3.6 13.9
Any drug 40.4 49.0 51.6 45.8 34.2 23.4 15.4 34.9
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For ethnicity, in the 2001/2 British Crime Survey of 16- to 59-year-olds, respondents 
of mixed ethnic background had the highest rates of reported drug use, with 25% 
reporting any illicit drug use in the past year.  People from Asian backgrounds 
tended to have lower reported rates of drug use (at 5%), while people of white and 
black ethnic origins were similar in reported levels of drug use (both 12%) (Aust and 
Smith 2003).  Aust and Smith suggested that the high rates of reported drug use 
among those of mixed ethnic background may be related to their socio-economic 
position, with high levels of indicators of deprivation in this group.
The data presented above relates to drugs that are classified under the Misuse 
of Drugs Act.  There are also volatile substances, such as amyl nitrate, glues and 
solvents, that are illegal to sell if it is likely that they are intended for abuse.  In 
2005/6, 8.4% of BCS respondents aged 16–59 reported that they had ever used 
amyl nitrate, and 2.4% reported that they had ever used glues or solvents.  Recent 
use of both types of substance was reported most frequently by respondents aged 
16–19 (Roe and Man 2006).
Trends among youth
So far we have presented data only on recent prevalence.  Of equal interest is 
how the prevalence of use has changed in recent years.  Unfortunately because of 
changes in survey methodology it is not possible to examine changes before 1998.  
Table 2.2  Figures for the proportion of 16- to 59-year-olds reporting having used 




















Cannabis 21.8 21.2 14.8 9.4 5.2 2.5 1.1 8.7 
Any cocaine 3.9 7.6 4.7 3.0 1.5 0.2 0.0 2.4 
Ecstasy 3.0 5.4 3.7 2.1 0.6 0.0 – 1.6 
Amphetamines 2.7 3.8 2.7 1.6 0.9 0.2 0.1 1.3 
Opiates – – – – – – – 0.1
Class A 6.3 10.3 6.9 4.3 1.8 0.3 0.1 3.4 
Any drug 24.8 25.6 17.5 11.7 6.6 2.9 1.5 10.5 
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Figure 2.1 indicates that the prevalence of drug use (predominantly cannabis) in the 
last year rose among school pupils aged between 11 and 15 from 1998 to 2000.  After 
that the patterns differ by specific age.  It fell for 13- to 15-year-olds (NatCen/NFER 
2006) but not for 11- and 12-year-olds.5  The proportions of pupils reporting monthly 
use of drugs seems to have stabilised in England and to be falling in Scotland 
(ACMD 2006).  Drug use among young people in Northern Ireland was lower than 
in other parts of the UK during the years of civil unrest, but appears to have been 
rising since the ceasefires following the 1998 Good Friday Agreement (Higgins  
et al. 2004).
Figure 2.2 suggests that there has been a moderate fall in the prevalence of 
cannabis use among young people above school age in England and Wales since 
1998.  From the figures available so far, use of cannabis does not appear to have 
been significantly affected by the reclassification of the drug in January 2004.  
Ecstasy use appears to be fairly stable, around the 5% level of prevalence, with 
some evidence of decline since 2001/2, though prices have fallen rapidly.  When 
ecstasy first became popular in British nightclubs, pills were sold for between £15 
and £20.  Independent Drug Monitoring Unit (IDMU) figures suggest that average 
prices had fallen to under £10 by 1997 and were less than £4 in 2004.  There seems 
to be a natural history to the use of ecstasy, as most users stop before they have 
used it 40 times (Eiserman et al. 2005).  It is not an addictive drug.  So, unlike 
heroin, reductions in initiation into the drug will soon translate into significant 
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Use of volatile substances has apparently fallen since 1998.  The BCS reports that 
prevalence of reported use of amyl nitrate by 16- to 24-year-olds fell from 5.1% in 
1998 to 3.9% in 2005/6.  The reduction for glues and solvents was from 1.3% to 
0.5% in the same period (Roe and Man 2006).
There has been a debate over whether ‘recreational’ drug use, especially of 
cannabis, has become a ‘normal’ activity among young people in Britain (Parker 
et al. 1998a).  In response to critics of this idea, such as Shiner and Newburn 
(1999), Parker (2005) has argued that drug use increased rapidly in the 1990s, 
being reported in surveys by about 1 in 3 young people at the end of the decade, 
compared to around 1 in 5 at the beginning.  ‘Recreational’ drug use appears now 
socially accommodated, as suggested by the growing body of research that shows 
that, although there continues to be a minority of young people who strongly reject 
drugs, they have become a regular part of life for many young people.  Non drug 
users tend to have friendships with drug users and accept, however reluctantly, their 
friends’ choices to use these drugs.  Parker also refers, with support from Blackman 
(2004), to the cultural accommodation of drugs that is apparent in the increasingly 
neutral or even positive portrayals and mentions of drugs in mainstream films and 
TV programmes.  
British youth culture has changed since the high tide of dance culture in the late 
1980s and early 1990s.  As fashions change, it is possible that drugs such as 
ecstasy, amphetamines and LSD are losing out in competition with other attractions. 
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recently increased, as the alcohol industry and local authorities have promoted 
the night time economy, in which the development of new alcohol brands, venues 
and later drinking hours have drawn more young people and their money into city 
centres.
Parker (2005) also highlights the co-occurrence of alcohol with illicit drug use as 
one of the dangers attendant to the normalisation of recreational drug use.  Among 
his ‘illegal leisure’ study sample at age 22, 78% were drinking alcohol when they 
last took an illegal drug.  Heavy drinking and mixing of psychoactive substances 
pose serious challenges to public health, including dangers during the journey 
home, depression and diseases associated with longer term alcohol misuse.  
Combined use of alcohol and cocaine produces a third substance, cocaethylene.  
Combining cocaine and alcohol use may increase the risk of damage to the brain 
(Bjork et al. 2003) and heavy drinking represents a serious threat to the health 
of cocaine users (Gossop et al. 2006a).  Parker also notes that there is ‘slippage’ 
from recreational to problematic patterns of use.  Many of the new heroin users he 
identified in his 1998 study did not come from the usually vulnerable groups, but 
had moved on to heroin through social networks they developed in the recreational 
scene.
Heroin
Heroin is associated with more damage, over a longer period of time, than any 
other illegal drug in the UK.6  This is not because heroin itself is the most dangerous 
substance available.  In its pure form (diamorphine), heroin has few long-term 
physiological effects and has been taken safely for many years by some people.  
Others are able to control their use of heroin, contradicting popular notions that 
addiction is an inevitable consequence of heroin use (Warburton et al. 2005, 
Shewan and Dalgarno 2006).  But many users do experience overdoses and the 
harmful consequences of dependence.  Heroin has been at the centre of British 
concerns about illicit drugs since the mid-1960s and, even with the rise of crack 
and cocaine, continues to account for most of the harm related to illegal drugs; 
for example, 86% of the estimated number of problematic drug users are users 
of heroin (Hay et al.  2006).  Thus we give it more space than any other drug in 
describing how its use has evolved.
Heroin is the drug that is classically associated with ‘epidemics’ (Hunt 1974).  The 
notion of a drug epidemic captures the fact that drug use is a learned behaviour, 
transmitted from one person to another.  Although there are individuals – drug 
importers and distributors – who consciously seek to create new markets for their 
drugs, it is now clear that almost all first drug experiences are the result of being 
offered the drug by a friend or family member.  Drug use thus spreads much like a 
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communicable disease.  Users are ‘contagious’, and some of those with whom they 
come into contact are willing to become ‘infected’.  
In an epidemic, rates of initiation in a given area rise sharply as new users of a drug 
initiate friends and peers (Caulkins et al. 2004).  At least with heroin, cocaine, and 
crack, long-term addicts are not particularly ‘contagious’.  They are often socially 
isolated from new users.  Moreover, they usually present an unappealing picture 
of the consequences of addiction to the specific drug.  In the next stage of the 
epidemic, initiation declines rapidly as the susceptible population shrinks, because 
there are fewer non users, and because the drug’s reputation sours, as a result 
of better knowledge of its effects.  The number of dependent users stabilises and 
typically gradually declines.
In most Western countries there has been just one discrete heroin epidemic.  
That is true for example of the Netherlands and the United States, both of which 
experienced an epidemic of heroin use between the late 1960s and early 1970s; 
since then each has had only moderate endemic levels of initiation.  The United 
Kingdom is different.  Though none of the indicators of the size of the heroin-
addicted population is unimpeachable they generally rise rapidly almost without 
pause throughout the 25-year period 1975–2000.  There are references in the 
literature (e.g.  Parker et al. 1998b) to two epidemics, one in the 1980s and one in 
the 1990s, but there is not the sharpness of distinction in rates of change in different 
time periods that this suggests.  
Figure 2.3 provides data on the number of ‘addicts notified to the Home Office’ for 
1960–96; some of the notifications were new, while some were re-notifications of 
dependent users who had been in the system at some previous time.  This series 
was maintained from 1935 to 1996, making it uniquely long.  Notification was 
voluntary until 1967, but was made compulsory by the Dangerous Drugs Act of that 
year.7  The numbers were always dominated by heroin notifications.  The figures 
were fairly stable until about 1960 and then rose in relative terms quite sharply until 
1967, with most of this rise occurring in London.  This geographically concentrated 
increase led to a major change in policy, although there was no national epidemic 
of heroin addiction.  The number of notifications remained stable for the next ten 
years, until about 1976.  If the series after 1976 is broken into five-year periods, 
in each of those periods the number roughly doubled.  In 1976 the number of 
notifications was less than 2,000; twenty years later it was more than 40,000.  Few 
health indicators have shown such rapid deterioration over such a long period.
For purposes of tracking the emergence of a heroin epidemic, a more relevant 
series is that on ‘new notifications’ (as opposed to those who had been notified by 
a doctor in some earlier year as well) for heroin specifically.  The number of new 
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notifications in a given year is an indicator of initiation into dependent use in the 
previous few years.  Though there is a delay from first year of dependence to first 
notification, a substantial proportion of those who became dependent were likely 
within a few years to come into contact with a physician who might report that 
dependence (Millar et al. 2004).  The series for new notifications of heroin use for 
the period 1975–96 is given in Figure 2.4.  The pattern is essentially the same as in 
Figure 2.3; the number increases by about 15% per annum over that period.  In 1975 
the number of new notifications of heroin dependence was 525; in 1996 the figure 
was just over 15,000, with large proportional increases in each five-year period, with 
a notable peak in 1985 and a pause from then to about 1990.  (See also Strang and 
Taylor, 1997.)
After 1997 the series was ended, to be replaced by indicators from the Regional 
Drug Misuse Databases.  For the period 1997–2004, there is no single indicator that 
is as authoritative as the notification series.  There is, however, a larger number 
of indicators that can, with caution, be combined to tell a consistent story, namely 
that the numbers of addicts continued to rise until about 2000 and, less clearly, 
may have stabilised after that.  The indicators available are treatment enrolment, 
mortality and seizures.  The number of treatment admissions in the six-month 
period ending September 2000 was 50% higher than that in the six-month period 
ending September 1997.  Deaths from drug misuse, the majority of which are for 
opiates, rose by 25% from 1997 to 2000 in England and Wales; for Scotland8 the 
number rose by 150% in the same period.  Heroin seizures, which are of course also 
driven by police decisions as well as quantity consumed, rose by 30 % between 
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After 2000 there appears to be a downturn or stabilisation.  Death figures decline 
for England and Wales and they have fallen in Scotland since 2002 (though deaths 
related to heroin and/or methadone vary).  Heroin seizures also decline from 
2001 to 2004.  These suggest decrease or at least stability in consumption, given 
increased enforcement activity.  As discussed in Chapter 4, treatment enrolment 
doubled between 1998 and 2005.  This is probably driven not by increasing heroin 
addiction but by the efforts of the government, under its 1998 strategy, to increase 
the availability of treatment and to use the Criminal Justice System to increase 
treatment enrolment.  
This analysis suggests that heroin addiction increased rapidly and steadily over at 
least a 20-year period and perhaps for 25 years before stabilising at levels that are 
very high by international standards, as discussed later in this chapter.  Providing 
some support for this are data on opiate-related deaths, which in England and 
Wales rose from less than 50 in 1975 to about 900 in 2000.  Other studies, using 
more sophisticated modelling techniques with other data, have generated similar 
conclusions.  More recent research from the North West of England also supports 
the notion that, during the 1990s, initiation into heroin use may have started to fall 
in areas that had seen big increases in the 1980s (although it may still be increasing 
in other areas) (Millar et al. 2006).
One possibility is that there have been a series of local epidemics at different points 
in time and that they aggregated to a smooth increase in the number of addicts 
over a long period of time.  The US heroin epidemic has been mapped as a series of 
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1976), but these occurred over a small number of years, 1968 to 1973.  Moreover, 
the British literature makes frequent reference to geographically specific epidemics 
at different times.  For example, Ditton and Frischer (2001) provide analyses for 
Glasgow that show roughly a ten-year period (1985–95) of high incidence.10  Pearson 
and Gilman (1994) refer to variations within Northern England, where it struck west 
of the Pennines earlier than it did to the east.  Rates of drug-related death continue 
to vary widely between areas (Ghodse et al. 2006).  
Heroin was initially an urban drug, not available much outside London in the 
1970s.  Parker et al. (1988) showed how, in the 1980s, heroin spread into socio-
economically deprived area, with the new users predominantly recruited from the 
ranks of unemployed young men.  Though there is the occasional story involving 
a prominent family and heroin addiction, it is still more common in economically 
deprived neighbourhoods (Pearson and Gilman 1994).  
The heroin-dependent population has been historically at least two-thirds male.  
Strang and Taylor (1997) note that the proportion of males among new heroin 
notifications rose sharply in the 1990s.  Age of first use of heroin is typically 
about 21.  Careers of heroin dependence are clearly long for those who are unable 
to desist quickly and who lack the opportunities that support natural recovery 
(Granfield and Cloud 2001).11  Among those notified for the first time in the period 
1975–85 approximately one-quarter were under the age of 21 and the average age 
was 25.  Given that these were notifications of dependence and required contact 
with a physician, this suggests initiation at an early age.  The median age of those 
in treatment in 2004 remained relatively young, only about 30 (NTA 2005b).  This 
contrasts, for example, with the treatment population in the USA, where the median 
age for heroin patients is 36 (SAMHSA, 2005).
The rise of cocaine and crack
Cocaine has been a notable feature of British drug history, even if concern has 
tended to focus on heroin, and cannabis has been more widely used.  There was a 
period in the late nineteenth century when cocaine was enthusiastically promoted 
by medical journals and followers of Freud, and coca was used in the manufacture 
of freely available patent medicines and tonics.  Concern over its abuse by chemists 
and then by soldiers led to increasing regulation of cocaine, alongside heroin, in, 
for example, the Dangerous Drugs Act of 1920 (Bean 1993).  Use was probably very 
slight for the following fifty or sixty years.  
Although virtually non-existent in the UK between 1960 and 1980 it did become 
associated with leisure pursuits of the rich and famous.  Despite its use by heroin 
injectors in speedballs12 and the prescription of cocaine to addicts, there was an air 
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of exclusivity attached to its high price and ‘champagne’ image.  Two factors have 
changed this picture in more recent years; the advent of crack and the spread of 
powder cocaine out of fashionable metropolitan circles.  
Initial concern over crack peaked in the late 1980s, following dramatic warnings that 
Britain was on the brink of a surge of crack use as South American drug traffickers 
sought to replicate their success in marketing the drug in American cities.  However, 
Figure 2.2 suggests that crack use is still rare among the kinds of young people who 
respond to household surveys.  Likewise, in the Scottish Crime Survey, use of crack 
in the past year was reported by 0.2% of respondents in 2004 (Murray and Harkins 
2006).  Some groups of people are considerably more likely to have used crack.  A 
study of 160 homeless people under 25 in four cities found that 38% of them had 
ever used crack (compared to 2% in the 2000 British Crime Survey) (Wincup et al. 
2003).  The geographic spread was uneven; it was far more commonly reported in 
Birmingham than in Cardiff or Canterbury (Wincup 2006).  
Crack is often used by people who have problems with other drugs.  It has recently 
been estimated that there are approximately 193,000 recent users of crack in 
England and Wales, with a large overlap with heroin users.  The estimated number 
of recent crack users in London is almost as large as that of heroin users (Hay et 
al. 2006).  Despite the increasing prevalence of crack use among problematic drug 
users, in 2003/4, only about 7,500 (6%) of those who entered drug treatment in 
England reported crack as their main problem drug, but again with wide regional 
variations (from 2% in the North East to 23% in London) (NTA 2005a).13  Currently 
it seems that crack, while not widespread, is used by a large proportion of the 
homeless and drug dependent populations in those urban centres where crack 
markets have been established.  
Figure 2.2 (page 23) indicates an increase since the late 1990s in the use of powder 
cocaine among young people.  It is estimated that over three-quarters of a million 
people in England and Wales used powder cocaine in 2005/6 (Roe and Man 2006).  
Prevalence of last year cocaine use also increased from 1.5% in 1993 to 4.6% in 2004 
for all age groups in the Scottish Crime Survey (in 2004, it was reported by 5.2% of 16- 
to 19-year-olds and 14.1% of 20- to 24-year-olds) (Murray and Harkins 2006).14 
Of those who entered treatment for drug problems in England in 2003/4, 4% 
reported their main problem drug as cocaine.  It seems that the powder form of 
cocaine is used less frequently by dependent drug users.15
The increase in cocaine use has been attributed partly to the falling price of the 
drug.  According to the Serious Organised Crime Agency’s latest assessment, the 
average street price of a gram of cocaine fell from £69 in 2000 to £49 in December 
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2005 (SOCA 2006).  Another factor may be changes in the image of the drug and 
its pattern of diffusion among young people.  From being an exclusive drug, used 
only by the wealthy and some dependent drug users, it has now become part of the 
menu of psychoactive substances that young people use to enhance their leisure 
time.  It may have come into fashion among these people as ecstasy reduced in 
perceived quality (Measham 2004).  
International comparisons
Comparing the situation in the UK to other countries may assist us to understand 
the specific nature of the British drug problem, and the effectiveness of potential 
policy responses.
Internationally, the UK shows high rates of drug use.  Estimated lifetime prevalence 
of cannabis use is higher in England and Wales than in any other European country, 
although lower than in the USA and Australia (Roe and Man 2006, SAMHSA 2006, 
EMCDDA 2006, AIHW 2005).  As shown in Figure 2.5, British countries also have the 
highest rates of recent cocaine use in Europe, although recent use of cannabis is 
reportedly higher in France.
In addition to high rates of drug use, the UK also has relatively high rates of 
problematic drug use and drug-related death, as shown in Figures 2.6 and 2.7.  
These figures suggest that, as is often the case for social indicators, the UK falls 
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Conclusion
From this review of the pattern of drug usage, we conclude that drugs have become 
an increasingly common feature of British life over the past 30 years.  Most young 
people now have contact with drugs, and many of them have experience as drug 
users.  The mixture of drugs that people take fluctuates over time.  Cannabis is still, 
as in most developed countries, the most commonly used illicit drug.  The popularity 
of ecstasy seems to be waning.  Amphetamines and LSD, which were so closely 
associated with 1960s drug culture, are now minority tastes, even among active 
drug users.  
Only a small proportion of users will go on to have problems with drugs.  However, 
the number of people who do have serious problems with drugs has increased 
hugely since the 1970s.  Heroin is still the drug that is associated with most of 
this problematic use, although crack has become a significant element of the drug 
problem in some areas over the last few years.  The most concerning aspects of 
contemporary drug use are the historically high level of heroin use, its interaction 
with the spread in crack markets and the harms that may arise from young people 
mixing alcohol and other drug patterns and moving between recreational and 
problematic use.
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CHAPTER 3
Drug problems in Britain
The link between drugs and drug problems is both direct and indirect.  The problems 
arise from a combination of the psychopharmacological properties of the drug, the 
method of use and the choices and circumstances of the user.  
The main problems that have been associated with drug use in Britain in policy 
discussions are:
•   death;
•   health problems;  
•   crime.
Before looking in more detail at specific harms, it is worth making the general 
point that these harms are very unevenly distributed through British society.  Some 
people and neighbourhoods are much more vulnerable to drug-related harm 
than others.  These tend to be the people and communities that also suffer social 
exclusion.  Studies suggest that socially excluded groups of young people, such as 
school truants and excludees, offenders, children in the care of local authorities and 
those with parents who use drugs, tend to report higher rates of drug use than other 
young people (Budd et al.  2005a, Goulden and Sondhi 2001).  For adults, while 
‘recreational’ drug use is not necessarily more prevalent among socially excluded 
groups,1  more harmful patterns of drug use are typically reported by people who are 
unemployed, unqualified, in financial difficulties and homeless or living in rented or 
unstable accommodation (Coulthard et al. 2002, Wadsworth et al.  2004).  It seems 
that socio-economic deprivation is associated with drug dependence, but not drug 
use (von Sydow et al. 2002, Stevens 2003).  
Other social problems such as victimisation by murder, burglary and robbery, poor 
health, road traffic accidents and early death also tend to concentrate in deprived 
areas (Dorling 2006).  Drug problems tend to ‘huddle together’ with social problems 
to deepen the miseries of those who have been left behind by economic growth 
(Pearson 1991).  For example, analysis of BCS and Census data has found that over 
half of all property crime is found in the poorest one-fifth of communities in England 
and Wales (Hope 2001).  An analysis of data from the psychiatric morbidity survey 
found that the most socially deprived people were 10 times more likely to report 
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drug dependence than those who reported no indicators of deprivation (ACMD 
1998).  A 2003 investigation into drug-related deaths in Scotland found that 42% of 
those deaths took place in the most deprived neighbourhoods, comprising only 19% 
of the population (Zador et al.  2005.).2
Death
Drug users can die from a variety of causes.  An overdose of opiates can cause the 
user to stop breathing.  Cocaine overdose can lead to fatal heart or respiratory 
failure.  Drugs may superimpose their toxic effects on other medical conditions, 
such as asthma, epilepsy, or cirrhosis of the liver.  Drug use methods can transmit 
life-threatening infectious diseases.  And drug intoxication can contribute to deaths 
from car crashes and other accidents.  There is no official estimate of the mortality 
rate for drug users, but a study of three English cities found annual opioid mortality 
rates among injecting drug users of between 0.8% and 2.1% (Hickman et al.  2004).  
This includes deaths from overdose, but not from other causes to which drug users 
are vulnerable, including accidents and chronic diseases.  The mortality rate for 
heroin users in a study in London was 17 times higher than that for non-heroin users 
(Hickman et al.  2003).
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recording the cause of death and the drugs related to it.  The official definition is 
‘deaths where the underlying cause is poisoning, drug abuse, or drug dependence 
and where any of the substances are controlled under the Misuse of Drugs Act 
(1971)’.  There were over 1,700 such deaths in 2004 in Great Britain.  An analysis of 
deaths in 2000 suggested that 77% of them involved acute overdoses (Webb et al. 
2003).  
Figure 3.1 shows that heroin was by far the most common illicit drug mentioned in 
death certificates in 2004.  It was mentioned on 483 death certificates as the only 
drug and on 744 certificates in total.  Cannabis was not the sole drug mentioned on 
any death certificates.  It was mentioned on 14 death certificates alongside other 
drugs (ONS 2006).
It has been suggested that true heroin overdoses are relatively rare, compared to 
cases where the level of heroin in the blood is not fatal of itself but combines with 
the effect of other drugs to contribute to ‘multiple drug toxicity’ (Darke and Zador 
1996).  However, a study in Sheffield did not find lower levels of heroin in the bodies 
of those who had also used other drugs, compared to those who died after use of 
heroin alone.  It suggested that a period of abstinence, as a result of imprisonment 
or hospitalisation, is a risk factor for overdose in those who relapse to heroin use 
(Oliver and Keen 2003).  This suggestion has been confirmed in studies of released 
prisoners (Bird and Hutchinson 2003) and of people leaving inpatient detoxification 
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Success in reducing drug-related deaths is most likely to come from reducing 
overdoses among heroin users and from increasing the promptness and 
effectiveness of emergency resuscitation.  This has been the target of recent 
interventions, such as the guidance issued by the National Treatment Agency  
(NTA 2004) and the Scottish Executive’s production of a DVD (titled Going Over)  
and funding of associated first aid training for drug users and service providers.  
Figure 3.2 shows that Scotland has a higher rate of drug-related death than England 
and Wales.  The trend in all three countries seems to be falling from peak levels in 
recent years.  The death rate has increased and then fallen in the period since 1998, 
leaving no overall change in Scotland, and a reduction of 7% in England and Wales.  
Health
The Home Affairs Select Committee (2002) recommended that an explicit target 
on public health should be included in the drug strategy.  In its response, the 
government accepted this need and referred to its target to reduce drug-related 
death by 20% by 2004 (which was missed) (Home Office 2002).  However, the 
headline targets of the drug strategy, as incorporated in the public service 
agreement on drugs policy, still do not include direct indicators of public health.
The other drug-related health problem that has received most attention from policy 
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injecting drug users (IDUs) to the wider population (Moss 1987).  Incidence of HIV 
among IDUs peaked in 1986, and AIDS incidence and related deaths peaked in the 
mid 1990s.  By the end of 2005, only 5.6% of all UK cases of HIV were attributed 
to injecting drug use (HPA et al.  2006).  However, there is worrying evidence that 
HIV is now on the increase among IDUs.  HIV prevalence among current injectors 
has been increasing in London since 1996 and started to rise in the rest of England 
and Wales in 2002 (The UK Collaborative Group for HIV and STI Surveillance 2005).  
There was an increase in prevalence between 2002 and 2005, from 0.9% to 1.6% 
(HPA 2006).  The number of new HIV infections among IDUs in Scotland rose from 
a low of 10 in 2002 to 24 in 2005 (Scottish Executive 2006b).  It is possible that 
these increases are linked to the rise in crack use, which is associated with riskier 
injecting practices (Rhodes et al. 2006).  Although these numbers are still small, 
these increases are important, as they bring prevalence closer to the level where an 
epidemic could rapidly accelerate.  The UN has noted that prevention efforts should 
keep HIV prevalence in IDUs below 5%, or risk a very rapid spread (UNAIDS 2001).  
European comparisons on HIV
Figure 3.3 presents data on HIV prevalence among injecting drug users in a number 
of European nations.  The available data on HIV prevalence suggests that British 
rates are similar to those in countries with much lower rates of drug use prevalence 
and drug-related death (see Figures 2.6 and 2.7).  This may well be due, at least in 
part, to the different policies that have been pursued.  The United Kingdom has an 
international reputation as one of the first countries to respond effectively to the 
threat of HIV among IDUs.  Relatively early in the global HIV pandemic, following 
the 1985 finding that 50% of drug injectors in Edinburgh were HIV positive and 
the subsequent ACMD (1988) AIDS and Drug Misuse report, the UK government 
endorsed and funded interventions that are still controversial in many countries, 
such as needle exchange and the expansion of methadone treatment and outreach 
to drug users (Stimson 1996, Strang 1998).  These were effective in the 1990s 
in limiting the spread of HIV to below that found in injecting drug users in other 
countries (Hope et al.  2001).
Other countries waited until much later in their epidemics before introducing such 
measures, but found that they were effective when they did.  The most striking 
case of this is Spain.  Spanish drug policy was dominated until the early 1990s by 
attempts to enforce abstinence, with very limited efforts to reduce the transmission 
of infectious disease (Rinken and Vallecillos 2002).  This led to Spain having the 
highest rates of HIV infection among injecting drug users in Europe.  From 1992–94 
large-scale harm reduction programmes were introduced, which have produced 
significant reductions in the incidence of HIV (Hernandez-Aguado et al. 1999).  
However, due to the delay in introducing these measures, the prevalence of HIV 
among injecting drug users in Spain remains high.
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A team of researchers recently found higher than expected rates of HIV and hepatitis 
C infection in a study in London.  They suggested that this was due to high risk 
injecting practices, associated with newer injectors and the injection of crack (Judd 
et al.  2005).4 They found higher rates of hepatitis C in their sample than in many 
other cities internationally (Hope et al. 2001).  
Viral hepatitis 
Figure 3.4 suggests that hepatitis C infection from injecting drug use has risen 
rapidly  from under 350 known new cases in 1992, to over 9,000 in 2005.5  Estimates 
of the prevalence of hepatitis C infection among IDUs have most recently been 
reported at 64% in Scotland and 42% in England.  Over 90% of known cases of 
hepatitis C involve injecting drug use (HPA et al.  2006).
Hepatitis C is itself associated with a range of diseases, most importantly cirrhosis 
and cancers of the liver.  It used to be thought that the percentage of people who 
had hepatitis C that went on to develop life-threatening conditions would be small.  
However, more recent studies suggest that the effects of the virus accelerate with 
age, and large proportions of people living with it will die from liver disease, but 
only if they are not treated.  As many as 70% of people living with hepatitis C will 
develop liver disease and may require liver transplants (D’Souza et al.  2005).  The 
current supply of donated livers would be completely inadequate to this task, 
and the cumulative costs to the NHS could be as high as £8 billion (University of 
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that as many as 60% of these people could be effectively cleared of the virus 
(Poynard 2004).  And, contrary to received opinion in some medical quarters, these 
treatments can be provided effectively to current drug users (Foster 2006).  
Despite the potential public health benefits and future cost savings of treatment, 
it has been estimated that only between 1 and 2% of those living with hepatitis C 
receive treatment each year, compared to 13% in France (University of Southampton 
2005).  Many drug users with hepatitis C do not know they have the disease, and 
may be unwittingly passing it on.  The proportion of those unaware they had the 
disease was estimated to be 48% in 2005 (HPA et al. 2006).  Many of them also 
face barriers to entering treatment.  For example, it is only recently that the official 
guidance has been changed to state that even people who have mild hepatitis C, 
including current injecting drug users, should be offered treatment (NICE 2006).  
Awareness of this new guidance is low amongst those who could benefit from it.  
Alcohol use increases the risk of mortality from hepatitis C, so effective services for 
IDUs who have alcohol problems are also required.  
In contrast to hepatitis C, there is a vaccine for hepatitis B and drug treatment 
agencies are recommended to offer it to their clients.  The annual number of new 
notified hepatitis B infections among IDUs in Britain rose by 120% from 1992 to 
284 notifications in 2003.  But the estimated proportion of current IDUs who are 
living with hepatitis B fell from its 1992 peak of 35% to 19% in 2005 (HPA et al. 
2006).  This suggests that the rise in notifications may be due to increased testing 
and reporting.  Although the uptake of the vaccine is increasing, a survey of IDUs 
in contact with treatment in 2005 found that 41% had not been vaccinated (ibid.).  
This suggests the need for continued efforts to increase the uptake of hepatitis B 
vaccination.  It has been argued that there should be universal vaccination, as the 
drug users who are most at risk of infection are least likely to be offered the vaccine 
and to accept it (McGregor et al. 2003).
Cannabis and mental health
Mental health problems are another potential consequence of drug use.  Much of 
the debate around the reclassification of cannabis has focused on this risk.  The 
drug has been linked to three types of mental health problem: schizophrenia, 
depression and anxiety.  It has been argued that cannabis is so dangerous to mental 
health that it should not have been reclassified, but should be more rigorously 
controlled (e.g.  Phillips 2004).  This argument rests on two premises.  The first is 
that cannabis causes mental health problems (rather than just being correlated with 
them).  The second is that strict legal control can reduce the prevalence of cannabis 
use and therefore the consequent harms.  
The available research suggests that cannabis does indeed have an effect in causing 
Drug problems in Britain
39
schizophrenia or schizophreniform disorder.  But, as the vast majority of cannabis 
users do not go on to be mentally ill, it is considered to be a modest risk factor 
that is most relevant to people who are already vulnerable due to environmental 
or genetic influences.  The ACMD (2005) concluded that cannabis use increases 
the lifetime risk of developing schizophrenia by 1%.  There is also evidence that 
cannabis use can aggravate and prolong existing schizophrenic disorders, and of a 
causal link with depression and anxiety (although this research is more ambiguous) 
(Hunt et al. 2006).
It has been argued that the effects of cannabis on mental health are of more 
relevance to clinical practice than they are to drug policy.  This is because the risk 
of psychosis from cannabis use represents a very small proportion of drug-related 
harm and the evidence suggests (as discussed in Chapter 4) that enforcement of 
cannabis controls has limited effects on its use, while the links between cannabis 
and mental health problems are important considerations in treating people who 
have cannabis or mental health problems (Pollack and Reuter 2007).
Other drugs have also been linked to mental health problems.  For example, ecstasy 
has been linked to long-term mental health problems and cognitive impairment, 
including memory loss (Morgan 2000), although it is difficult to disentangle the 
effects of ecstasy from those of cannabis and other stimulants as they tend to be 
used by the same people (Dafters et al. 2004, Gouzoulis-Mayfrank and Daumann 
2006).  Early use of amphetamines and dependent use of cocaine and crack have 
also been linked to an increased risk of psychosis (Farrell et al. 2002).  There is 
also increasing concern over the co-occurrence of mental illness and problematic 
drug use.  One study found an 86% prevalence rate of personality disorder among 
in-patients being treated for opiate addiction (Oyefeso et al.  1998).  Another found 
that more than a third of mental health patients also had substance use disorders 
(Menezes et al.  1996).  Such dual diagnosis exposes people to even greater risks, 
including suicide, self-harm and criminal victimisation (Hunt et al. 2006, Stevens et 
al. in press, Najavits et al. 2005, Miles et al. 2003).
Crime
Some people who are dependent on heroin or crack also commit very high numbers 
of crimes (as well as their drug offences).  Research on drug treatment has shown 
that it leads to significant reductions in both drug use and crime (see Chapter 
4).  However, the exact proportion of crime that is committed by drug users is not 
known, and there seems to be little relation between overall levels of crime and the 
prevalence of drug use.  
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The drug–crime link
The large scale of drug-related crime was initially suggested by anecdotal reports 
from police officers, who noticed that their custody suites were perpetually filled 
with persistent, heroin-addicted thieves.  This evidence was formalised by the 
New-ADAM (arrestee drug abuse monitoring) study, which found high rates of drug 
use by arrestees tested in its sampled sites.  The rate of positive tests for heroin 
was 28% in eight English sites and 31% in two Scottish sites.  The rate of cocaine 
positives was much higher in England, at 23%, than Scotland, at 3% (Holloway et al. 
2004, McKeganey et al. 2000).  
The New-ADAM study was taken to show that a high proportion of crime is 
committed by drug users, but it has been criticised for the unrepresentative nature 
of the sampled sites (Stimson et al. 1998).  The Arrestee Survey has since been 
developed and samples arrested offenders at 60 custody suites in England and 
Wales.  However, it suffers from a low response rate of 23% (Boreham et al. 2006). 
Table 3.1 shows the self-reported rates of drug and alcohol use of these offenders 
(which were corroborated by oral fluid tests to detect recent drug use).
It is unwise to extrapolate figures directly from those who are arrested to the much 
larger population of unknown offenders (Young 2004),6  and especially from a 
study in which less than a quarter of eligible arrestees took part.  But these figures 
suggest some interesting interpretations.  They show that high proportions of 
offenders have used drugs in the month before arrest.  The prevalence of dependent 
heroin use was high by comparison with the rest of the population, but was much 
lower than the 57% of arrestees who reported problematic or hazardous patterns 
of drinking alcohol.  The proportion of heroin, crack and cocaine users was much 
higher when looking only at acquisitive offences, backing up the studies that 
suggest that acquisitive offending tends to accelerate during periods of heavy drug 
use (e.g.  Anglin and Speckart 1988, Farabee et al. 2001, Budd et al. 2005b).
Table 3.1  Proportions of sampled arrestees reporting drug and alcohol use 
(adapted from Boreham et al. 2006).
Reporting drug/alcohol use Percentage of sampled arrestees
Use of cannabis in last month 46
Use of heroin in last month 18
Use of crack in last month 15
Use of cocaine in last month 10
Dependent use of heroin 18
Problematic or hazardous drinking 57
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There are several reasons for the link between drug use and crime.  The current 
drug strategy focuses on what is known as the ‘economic–compulsive’ link, which 
involves dependent users committing crime to get money to buy their drugs 
(Goldstein 1985).  In the Arrestee Survey, 15% of arrestees reported committing 
crime in the past four weeks to buy drugs (Boreham et al.  2006).  Goldstein 
suggested two other links, including the ‘psycho-pharmacological’, involving the 
direct effects of drugs in increasing aggression and reducing inhibition, and the 
‘systemic’.  This third type of link is often ignored in drug policy.  It describes violent 
offences that occur in the regulation of the illicit drug market.  Having no recourse 
to the law, drug distributors use violence to deter and punish those who break 
agreements or threaten market share.  
Of course, the link varies between drugs and across types of offence.  Cannabis and 
heroin use are rarely related to violence, which is more commonly associated with 
the use of alcohol, cocaine and crack.  The relatively low price of cannabis means 
that users do not regularly resort to stealing to finance consumption.  Data from the 
New-ADAM study suggested that heroin use was associated with shoplifting and 
that crack use was associated with fraud, handling stolen goods and drug dealing.  
Neither drug was associated, in analysis with controls for other characteristics of 
offenders, with burglary (Bennett and Holloway 2005).  
There are other factors in offenders’ lives that may explain some of the links 
between drugs and crime.  The environmental and developmental risk factors for 
crime and problematic drug use are similar.  For example, the Edinburgh Study of 
Youth Transitions has found that delinquency and use of Class A drugs are both 
more common for those who live in socio-economically deprived neighbourhoods 
(McVie and Norris 2006).  Displaying aggression in childhood and experiencing 
family conflict have also been associated with both drug use and offending in 
longitudinal studies (Ensminger et al. 2002, Hops et al. 1990, Shepherd and 
Farrington 2003).  Overall, reviews of the international evidence on drug-related 
crime have found that ‘little support can be found for a single specific and direct 
causal connection’ (Lurigio and Schwartz 1999) and that the connection should 
not be divorced from the context of poverty and disadvantage in which it usually 
operates (Seddon 2005).  
Reductions in crime
The head of the National Treatment Agency in England has told MPs that the current 
drug strategy is ‘crime-driven and treatment-led’ (Hayes 2001).  The large increases 
in spending on drug treatment have been justified, in part, by their intended 
effect in reducing crime.  However, crime has been falling since well before the 
implementation of the 1998 drug strategy, even though the prevalence of cocaine 
use has risen and heroin use has remained at relatively high levels (see Figure 3.5).  
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Crime peaked in England and Wales in the mid-1990s.  Since then, there have been 
particularly large falls in domestic burglary, which is now at less than half its peak 
level (Walker et al. 2006).  In Scotland, housebreaking also fell by more than half 
between 1992 and 2002.  Overall crime reported to the Scottish Crime Survey fell 
between 1992 and 1999, but has since risen again (McVie et al. 2003).  
There are many other influences on crime in addition to drug use.  They include 
unemployment, inequality, demographics, fashion, the availability and price of 
consumer goods, detection and imprisonment rates and the use of locks and other 
situational crime prevention measures.  The apparent lack of correlation between 
British crime rates and the prevalence of Class A drug use means that it may be 
difficult to discern the effect of drug policy on overall crime rates.  Therefore, 
changes in crime rates are not directly indicative of the effectiveness of drug policy.
Other harms
Other problems for the families of dependent drug users, the communities they live 
in and in the countries of drug production and transit, have received less attention 
and are difficult to quantify.  The assumption has been that eliminating or reducing 
drug use will naturally reduce them.  One example is the harm caused to families 
by dependent drug use.  The Hidden Harm inquiry into the needs of children whose 
parents are problematic drug users estimated that there are between 200,000 
and 300,000 such children in England and Wales (between 2% and 3% of all those 
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children under 16.  These children face a range of problems, including damage to 
their health, their development, their relationships and their education.  The inquiry 
recommended that, as well as aiming to reduce the numbers of problem drug users, 
agencies should aim to engage more problem drug using parents with services 
(ACMD 2003).  There is potential for conflict between these goals, if efforts to 
reduce the level of problem drug users discourage parents from accessing services.  
For example, it has been suggested that if more punitive approaches to drug using 
parents are introduced, this may make them less willing to seek help, for fear of the 
punishment they might face if they admit their drug use.
The harms that are tracked are primarily individual harms, partly because they 
are more readily measured.  However, illicit drugs also damage communities, 
most directly through the disorder and crime that are generated around markets 
for drugs.  The open sale and use of drugs is not merely social nuisance but can 
damage the reputation of an area (Lupton et al. 2002) and so is likely to damage 
investment and employment opportunities.  
The creation of a large source of illegal income also has potentially serious adverse 
consequences.  Pearson and Hobbes (2001) report mid-level drug dealers earning tens 
of thousands of pounds per month.  More recently, researchers interviewed ten drug 
dealers who were motivated by profit.  They reported an average weekly income of 
£7,500 (May et al.  2005).  Although most drug sellers are earning much less money, 
and spending most of it on their own drug use, young men in communities with high 
levels of drug selling may be attracted to that activity and away from education and 
legitimate, if low wage, jobs by the prospect of much higher earnings.  
In addition to drug-related harms within the UK, the supply of illicit drugs to the 
UK market is associated with serious harms in the countries of production and 
transit.  Such harms include crime, conflict, corruption, environmental damage and 
the destabilisation of local economies.  For example, in Colombia, the cocaine trade 
financed the growth of criminal cartels that have engaged in very high levels of 
violence and murder.  In the armed conflict that continues, despite improvements in 
the security situation since 2002, both the FARC and its paramilitary opponents have 
used cocaine to finance activities that include kidnaps and massacres.  Farmers in 
Colombia are often forced to grow coca through poverty or direct coercion.  This 
cultivation and the destruction of crops by aerial fumigation have damaged large 
areas of fragile Amazonian rainforest (Livingstone 2004).  The conflict in Colombia 
has spilled over into Ecuador and also into Brazil, which is an important country for 
both transit and consumption of cocaine.  Here, there are widespread allegations of 
corruption and murder by police forces working against (and sometimes in collusion 
with) drug-financed gangs, who carry out frequent attacks on the police and 
civilians.  Afghanistan provides another example of the deleterious effect of drug 
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production on the security and economy of drug producing countries.  These harms 
are related to the demand for drugs in the UK.  Their causes and costs are even 
harder to specify and estimate than drug-related harms that occur within the UK.  It 
is to the cost of these harms that we now turn.
Measuring drug-related harm
There is a range of drug-related problems in the UK, each of which causes 
significant harm to drug users and to the wider society.  Measurement of the scale  
of these problems is extremely difficult, but there have been attempts to measure 
the costs attached to illicit drug use and to develop an overall indicator of drug-
related harm.
Building on work at the University of York (Godfrey et al. 2002), a recent report has 
attempted to estimate the socio-economic costs that can be attributed to Class A 
drugs (Gordon et al. 2006).  The headline from this report was that Class A drug use 
cost the nation £15.4 billion in 2003/4 (equivalent to about 1% of UK GDP).  Of these 
costs, 99% came from problematic drug users and 90% came from drug-related crime. 
Figure 3.6 illustrates the extent to which these costs are dominated by crime, with 
over £9.7 billion in costs estimated to be incurred by victims of such crime and over 
£4 billion spent by the Criminal Justice System in dealing with these crimes.  However, 
these estimates are debatable.  They extrapolate from a relatively small number of 
highly criminally active drug users in the National Treatment Outcome Research Study 
(NTORS) sample to the much larger population of problematic drug users.  
Drug-related crime
Drug-related death
Health service use Social care
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There is a wider problem with this approach, which challenges the basis of such 
measurement of drug-related costs.  Zero drug use is not attainable.  What is the 
value of knowing the difference between what we observe and what cannot be 
attained?  It has been argued that what governments need to know is how much 
it is possible to reduce various social costs through attainable reductions in drug 
use (Reuter 1999).  Otherwise the government is chasing a chimera, never knowing 
whether what it has done is good enough.
The Home Office’s Drug Harm Index (DHI) attempts to overcome this problem by 
using changes in drug-related problems, rather than measuring their absolute 
values (MacDonald et al. 2005).  It looks at the year-to-year changes in various 
indicators of drug-related harm and then attaches a value to these changes, based 
on a calculation of the economic and social costs of each type of harm.  These values 
are calculated on debatable grounds.  In 2004, 70.5% of the weighting in the DHI 
was accorded to crime indicators, with 16.5% for domestic burglary.  Drug-related 
deaths made up only 21.1% of the total value of the DHI.  
Figure 3.7 shows the trend in the DHI from 1998 to 2004 (MacDonald et al. 2006).  
The reductions between 2002 and 2004 are mostly caused by reductions in the 
heavily weighted costs of drug-related crime, especially burglary.  These weightings 
are calculated using data on the proportions of crime that are drug related from 
New-ADAM and the Arrestee Survey.  However, as noted above, the proportion 
of arrestees who have used drugs is unlikely to be repeated exactly in the wider 
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resulting in an over-estimate of the proportion of all crime that is drug-related within 
the DHI.  Moreover, ‘drug-related’ does not imply causality.  The DHI defined crimes 
as drug-related when arrestees reported some use of heroin, cocaine or crack 
within the previous month.  So, while 46% of the Arrestee Survey sample had used 
these drugs in the previous month, only 18% had ever injected drugs and a similar 
proportion were assessed as being dependent (Boreham et al. 2006).  As reported 
earlier, analysis of the New-ADAM data has shown that neither heroin nor crack are 
associated with burglary, once other offender characteristics are controlled for.  The 
DHI therefore appears likely to have substantially overestimated the amount of 
crime that is truly drug-related.  This challenges the validity of the reported trend in 
drug-related harm.
There are a number of other limitations to the DHI, as pointed out by the 
commentaries of Newcombe (2006) and Roberts et al. (2006).  These include the 
exclusion of costs that are hard to measure, the use of indicators that change with 
recording practices and the value judgements that have been made, for example, 
in comparing the value of crime and deaths.  The cumulative economic costs of the 
innumerable crimes that are committed by drug users may be very high.  But do they 
really belong to the same order of cost as the devastating impact of losing children, 
siblings or parents to drug-related death?  The health harms of drug use (such as 
HIV and hepatitis C) may form a small proportion of the national burden of disease, 
and a larger part of the burden of crime.  But can we combine these figures into a 
tool that appears to tell us that it is more important to reduce the criminal than the 
health harms of problematic drug use?
The result of all these limitations is that the DHI is a partial indicator of drug-related 
harm.  It runs the risk of introducing unintended incentives to the performance 
management of the drug strategy.  For example, the Index would likely fall if the 
police were to start targeting more non drug users for arrest, thereby reducing 
the proportion of drug-related crime calculated from the Arrestee Survey.  The DHI 
has been acknowledged as internationally ‘pioneering work’ (Roberts et al.: 11) in 
tracking drug-related harm.  However, the limitations of the current version mean 
that it must be used cautiously for policy decision-making.  
Conclusion
This review of the problems associated with drug use has shown that there are a 
wide variety of drug-related harms.  The overwhelming majority of drug users do 
not cause apparent significant damage to themselves or others.  The small minority 
of drug users who develop frequent and dependent patterns of use cause a large 
amount of harm to themselves and wider society.  Crime and the impact on victims 
has been considered to cause the majority of costs associated with problematic 
Drug problems in Britain
47
drug use, although it is falling and the link between this reduction and drug policy 
is unclear.  Health harms, including HIV and hepatitis C, are increasing, and, despite 
recent reductions, drug-related deaths remain at a historically and internationally 
high level.  There is a particular problem with the rapid rise in hepatitis C infection 
among injecting drug users and the small proportion who have access to the 
effective treatments that are now available.  These and other drug-related harms 
are distributed unevenly, falling most heavily on the poor.  This is because it is 
people who are from socially excluded groups who are most likely to develop 
problematic patterns of use, to have family members who do so and to suffer 
criminal victimisation from drug users.  However, the scale and distribution of drug-
related harms is very difficult to quantify.  Progress is being made in developing the 
analysis of the cost and trend in drug-related harm, but the available indicators rely 
too heavily on data that is partial and of questionable validity in application.
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CHAPTER 4
The impact of current drug policies
The evidence presented so far in this report suggests that the prevalence of drug 
use and dependence has risen notwithstanding increasing legal control through the 
last third of the twentieth century.  Current policies represent an attempt to move 
beyond the failures of the past and to base the response to drug use on evidence 
of what works.  In this chapter, we will describe current policies and assess the 
effectiveness of the current mix of policies.  We initially discuss the standards by 
which the effectiveness of drug policies can be judged.  We consider the role of 
the Misuse of Drugs Act 1971, describe the existing UK drug strategy, and review 
current patterns of expenditure on drug policies, before looking at the impacts of 
these policies in enforcing these laws, in prevention of drug use and in treating drug 
users.
Our discussion of the effectiveness of British drug policy is deliberately modest.  
We consider the marginal impact of policies more than the effect of policies in their 
entirety, and we judge the effectiveness of components of drug policy against one 
another and not against some absolute standard of public value.  Thus, for example, 
in expressing doubts about the effectiveness of lengthy prison sentences for drug 
users and offering a more positive assessment of treatment, we are suggesting 
mainly that reallocating some resources from incarceration to treatment could 
be beneficial.  Completely eliminating imprisonment, or raising taxes to expand 
treatment radically, might be considered by some to be in the national interest, but 
any such broad conclusions would be even more speculative than the rest of this 
analysis.  Available data tell us relatively little about the likely effects of extensive 
changes in drug policy, and proposals for making major shifts in overall drug-control 
spending raise questions about the relative value of drug control and other public 
policy goals.  In any event, there is no serious political consideration of wholesale 
reform of current drug policy.
Misuse of Drugs Act 1971
The Misuse of Drugs Act 1971 (MDA), which has been on the statute book for 35 
years, provides the current legal basis for controlling the use and availability of illicit 
drugs.  In recent years, it has been used to punish increasing numbers of drug users 
and dealers, but it still only deals with a small minority of drug users.  Many people 
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have expressed concerns over the lack of effectiveness of the MDA in drawing the 
right balance between the dangers associated with each type of drug, in deterring 
drug use and in providing a fair, balanced and proportionate response to drug use 
by different (particularly ethnic) groups in society.  
The basis for the classification system in the MDA is presumably intended to be 
the harmfulness and danger that was associated with each type of controlled drug.  
This was the original justification for placing heroin and cocaine in Class A, and 
cannabis in Class B.  However, the Act gives no criteria of harm or dangerousness 
by which they may be judged.  This leaves a gap that has been filled by repeated 
debates over how harm should be defined, on which drugs are more harmful and 
about why the controlled drugs should be treated so differently to two licit drugs, 
alcohol and tobacco, each of which cause more mortality and morbidity than all the 
controlled drugs combined.  Since the introduction of the MDA, new substances 
have been included in the schedule of controlled drugs and various changes have 
been made to the classifications.  The House of Commons Science and Technology 
Committee most recently questioned the reasons behind the ACMD’s conclusion and 
the government’s adoption of placing fresh psilocybin ‘magic’ mushrooms in Class 
A.  They were concerned there was no clear evidence that their use carries a level of 
risk comparable to heroin and cocaine.
Prior to the reclassification of cannabis, it was argued by some commentators that 
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health problems (Phillips 2004).  The evidence on cannabis use to date suggests, 
however, that cannabis use continues to be less prevalent even since reclassification 
(Roe 2005, NatCen/NFER 2006).  
In 2004/5, 85,000 people were arrested for drug offences in England and Wales 
(Ayres and Murray 2005) and nearly 42,000 drug offences were recorded by the 
police in Scotland (Scottish Executive 2005c).  There have been significant increases 
in the number of offenders sentenced under the MDA since the early 1990s, 
as shown in Figure 4.1.  The reclassification of cannabis in 2004 seems to have 
contributed to a large fall in the use of fines and the ‘other’ category of sentences 
(which includes absolute and conditional discharges).  The trends of increases in 
community sentences, and of gradual reductions in the numbers imprisoned (from 
historically high levels) seem to have been unaffected (although, as discussed 
below, prison sentence length has tended to grow for drug offences).
This increase in the scale of punishment does not mean that the law directly affects 
the lives of a high proportion of drug users.  The number of offenders sentenced in 
2004 represented only 1.1% of the number of people who were estimated to take 
illegal drugs that year (Roe 2005).
In 2004, drug law offenders represented 6.3% of arrests in England and Wales, 
10.3% of sentenced persons, 10.1% of those given community sentences and 
16.2% of the prison population in Britain.  If these proportions also reflected the 
proportion of resources expended at these different stages of the Criminal Justice 
System (a very big ‘if’ indeed), then annual spending on enforcement of the MDA 
might be in the order of £2 billion (see Table 4.1).1
In 1971, a critic of the then Misuse of Drugs Bill predicted that, if it became law, it 
would not halt the increase in drug use, would be impossible to enforce and would 
therefore lead to selective enforcement, targeting the most visible and excluded 
drug users (Young 1971).  Now there are indeed concerns over the disproportionate 
impact of the use of the MDA (and stop and search powers) on certain ethnic 
minority groups.  For example, Home Office figures show that 14% of those arrested 
for drug offences in England and Wales in 2003/4 were of black ethnic origin (Home 
Office 2005c).  Only 78% were white, despite the 2001 Census figures showing 
that white people represent 89% and black people 2% of the English and Welsh 
population.  Furthermore, those black people who were arrested were less likely to 
be cautioned and more likely to be charged, sentenced and imprisoned than their 
white counterparts.  These amplifications of the disproportionate arrest rate for 
black people meant that in 2003/4, 22% of the people imprisoned for drug offences 
in England and Wales were black, compared to the 64% that were white (ibid.).  
These figures show that members of the black population are 7 times more likely to 
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be arrested and 14 times more likely to be imprisoned for drug offences than white 
people, despite their rate of drug use, as reported in the British Crime Survey, being 
no higher than for white people (Aust and Smith 2003).
This over-representation of black people raises important questions about the 
enforcement of the MDA in particular communities and is set against other earlier 
discussions of policing ethnic communities, and is not necessarily a result of 
institutionally racist enforcement of the MDA.  It is possible that the increased 
arrest rate for black people reflects the concentration of police resources on 
disadvantaged neighbourhoods, where black people are more likely to live, or the 
presence of a higher proportion of black drug users and dealers on the streets 
and therefore vulnerable to arrest.2  It may be that some ethnic groups are less 
likely to accept a caution by admitting guilt and so are more likely to be charged 
(Fletcher 2006).  The higher rate of sentence and imprisonment might reflect a more 
serious profile of offending by black drug offenders.  The Metropolitan Police’s own 
monitoring statistics also show that black people in London are more likely to be 
formally dealt with for cannabis possession than white people, and are more likely 
to be charged rather than cautioned.  Their report calls for closer examination of the 
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many factors that may explain this over-representation (Metropolitan Police 2006).  
Government agencies have a duty under the Race Relations (Amendment) Act 2000 
to monitor their actions for differential impact on ethnic groups and to take action if 
negative impact is found, even if this is not due to racism.
The MDA was examined in depth in the Police Foundation’s independent inquiry, 
chaired by Dame Ruth Runciman (Independent Inquiry into the Misuse of Drugs Act 
1971–2000).  Among its 81 recommendations, the inquiry called for changes, rather 
than replacement of the Act.  It proposed that the classification system be reviewed 
to clarify the criteria by which decisions on the dangerousness of each drug are 
taken.  Specifically, it recommended: 
•   reclassification of cannabis from Class B to C, meaning that possession would no 
longer be an arrestable offence and the maximum prison sentence for trafficking 
would be seven years;
•   reclassification of ecstasy and LSD from Class A to B.  These reclassifications were 
also recommended by the Home Affairs Select Committee (2002) report on drug 
policy;
•   reduction of penalties for possession of all classes of controlled drug.
Only one of these recommendations has so far been implemented, and not in the 
way that the inquiry suggested.  Cannabis was reclassified to Class C in January 
2004, but the law was simultaneously changed to increase penalties for trafficking 
to 14 years and to retain the power of arrest for possession.  The only legal change 
was that the maximum penalty for possession of cannabis was reduced from five to 
two years; it is not the law, but Association of Chief Police Officers (ACPO) guidance, 
which has created the presumption against arrest in favour of giving warnings to 
adults for simple cannabis possession offences in England and Wales.  The other 
recommendations have been rejected on the grounds that they would send the 
wrong message about the dangers of drugs (Home Office 2002).
This use of drug legislation to send messages was strongly criticised by a report 
of the House of Commons Science and Technology Committee (2006).  Among its 
sweeping criticisms of the current classification system, it argued that using it to 
send out signals to the public was in conflict with the stated purpose of categorising 
drugs according to harm and with the idea of basing policy on evidence (as there 
is no evidence that people respond to the signals emitted by classification).  The 
Committee also argued that the current classifications were anomalous and, 
in some cases, arbitrary.  In particular, it criticised the reclassification of fresh 
magic mushrooms into Class A.  It recommended that the Advisory Council on 
the Misuse of Drugs should review the classification of ecstasy in the light of 
evidence suggesting that it is not as dangerous as other Class A drugs.  It found no 
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persuasive evidence of a deterrent effect from classification and concluded ‘that 
the current classification system is not fit for purpose and should be replaced with 
a more scientifically based scale of harm, decoupled from penalties for possession 
and trafficking’ (ibid.: 4).3 
In its response to this report, the government reiterated its belief that the illegality 
of drugs deters people from using them, but offered no empirical evidence to 
support this belief.  It insisted that it is right to have magic mushrooms and 
ecstasy in Class A.  It acknowledged the need for more research on the impact 
of classification, but decided not to go ahead with the thorough review of the 
classification system that had been announced in January 2006 (Home Office 
2006a).  It seems that the long-running debate on the MDA has reached stalemate, 
with many critics adamant that change is necessary, while the government insists 
that the current legislative framework is still appropriate.
UK drug strategy: Tackling drugs together for a better Britain
The initial version of the current government strategy was produced and 
orchestrated in 1998 by the short-lived  ‘UK Drugs Czar’.  It built on an earlier 
document, Tackling drugs together, of the previous, Conservative, government.  
Both documents, as their titles suggest, emphasised partnership approaches to the 
drug problem, with responsibility for local delivery of the strategy being given to 
multi-agency Drug Action Teams (DATs) in England and similar bodies in Scotland 
and Wales.
The strategy placed emphasis on the use of evidence to inform development 
of policy and on accountability of the agencies involved in its delivery.  It was 
accompanied by an increase in expenditure on drug issues, and claimed that money 
would be shifted from reacting to drug problems to proactive prevention.  It was 
coordinated from within the Cabinet Office, which was also developing policy on 
reducing social exclusion.  
By the time the strategy was updated in 2002, responsibility for its coordination had 
moved to the Home Office, which ostensibly had a narrower, crime reduction agenda 
than the Cabinet Office.  Its targets were listed as:
•   Young people – ‘Reduce the use of class A drugs and the frequent use of any 
illicit drug among all young people under the age of 25 especially by the most 
vulnerable young people.’ 
•   Communities – ‘Reduce drug related crime, including as measured by the 
proportion of offenders testing positive at arrest.’ 
•   Treatment – ‘Increase the participation of problem drug users in drug treatment 
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programmes by 55% by 2004 and by 100% by 2008, and increase year on year the 
proportion of users successfully sustaining or completing treatment programmes.’
•   Availability – ‘Reduce the availability of illegal drugs’ and ‘contribute to the 
reduction of opium production in Afghanistan, with poppy cultivation reduced by 
70% within 5 years and elimination within 10 years.’
These targets were included in the 2002 Public Service Agreement (PSA) on ‘Action 
Against Illegal Drugs’, along with additional targets on cutting availability.  PSAs 
are agreements between the Treasury and government agencies that spend public 
money.  They determine the priorities against which these agencies will be held 
accountable.  In 2004, the drugs PSA was revised, and the specific targets on 
availability were dropped.  The current PSA targets are:
1  Reduce the harm caused by illegal drugs (as measured by the Drug Harm Index 
encompassing measures of health consequences of drug use, the availability 
of Class A drugs and drug related crime) including substantially increasing the 
number of drug misusing offenders entering treatment through the Criminal 
Justice System.
2  Increase the participation of problem drug users in drug treatment programmes 
by 100% by 2008 and increase year on year the proportion of users successfully 
sustaining or completing treatment programmes.  
3  Reduce the use of Class A drugs and the frequent use of any illicit drug among 
all young people under the age of 25, especially by the most vulnerable young 
people.  
Though quite sophisticated and analytic by the standards of national drug control 
strategies around the world, there are still various problems with the targets and 
the loose linkages between intended outcomes, processes and evaluation.  For 
example, there are problems with the indicators of their achievement.  As noted in 
Chapters 1 and 2, these indicators rely on data sources, such as the British Crime 
Survey, which may exclude the most vulnerable groups and, in the case of the Drug 
Harm Index, weight crime harms more heavily than health harms.  Inevitably there 
is a problem of collapsing real data into an arbitrarily constructed scale index.  
Moreover, it may be difficult to link changes in the indicators to actions from the 
strategy.  Even if indicators change over time, these changes may not be caused by 
the strategy.
As indicated earlier the Home Affairs Select Committee (2002) recommended that, 
in addition to a target on numbers in treatment, there should be targets on the 
number of overdoses and the number of new HIV and hepatitis infections.  These 
indicators and drug-related deaths are included in the Drug Harm Index, but its 
weighting ensures that their effect on it is overwhelmed by trends in crime.
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The main focus of implementation of the drug strategy has been the use of 
treatment and other initiatives to reduce drug-related crime.  This has included the 
development of several crime prevention initiatives and arrangements (including 
coordination between DATs and Crime and Disorder Reduction Partnerships, 
Communities Against Drugs initiative, the Drug Interventions Programme and 
the Tough Choices programme) and more coercive approaches to treatment 
(including the Drug Treatment and Testing Order, the Drug Abstinence Requirement, 
restrictions on bail, the Drug Rehabilitation Requirement, testing on arrest and 
required assessments).  As the perceived goal of treatment has shifted from 
reduction of drug use to reduction of crime, the treatment system has become 
more closely aligned with the Criminal Justice System (Duke 2006).  This has led to 
considerable discussion as to the efficacy of delivering treatment in this way.
The 2002 update of the drug strategy announced a 45% increase in planned 
expenditure between 2002/3 and 2005/6, with the largest increases in the budgets 
devoted to treatment and protecting communities (including some of the crime 
prevention programmes mentioned above).  The actual spending comes from the 
budgets of several departments and agencies and is difficult to relate to the plans 
announced in 2002 (for example, the NTA estimates treatment expenditure at £508 
million for 2005/6, compared to the planned amount of £573 million).  There is little 
transparency in the reporting of public expenditure on drug policy.4  
Figure 4.2 suggests that expenditure on supply reduction was planned to grow 
much more slowly than the treatment budget and is now smaller in absolute value.  
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on investigating, prosecuting and punishing drug dealers and users, for which we 
have made a crude estimate of about £2 billion (see Table 4.1).  This is several times 
higher than the expenditures on both drug supply reduction and treatment that are 
reported in the drug strategy.  This has led to calls from many quarters questioning 
whether British drug policy strikes the right balance between proactive spending on 
prevention of drug problems and reactive spending on detecting and punishing drug 
users and distributors.
Enforcement 
The utilitarian purpose of enforcing drug laws is presumably to reduce drug use by 
discouraging and preventing the distribution and use of drugs.  There are several 
methods by which enforcement of drug laws attempts to achieve these aims.  They 
include:
•   reducing demand for drugs by catching, punishing and sentencing users, 
suppliers and producers (including asset confiscation);
•   disrupting the operation of wholesale and retail drug markets;  
•   seizures of drugs at the point of importation;
•   eradication of crops in countries of production.
Current UK drug policy includes elements of all these approaches.  Below, we 
examine current policy and evidence on impact for each approach.
Reducing drug use by punishing users and dealers
The existence of legal penalties for possession of drug use is often justified on 
the grounds that they deter people from using drugs.  This claim is very difficult to 
evaluate, as there is no counter-factual example (i.e. a country identical to Britain, 
except for its drug laws) against which to compare the deterrent effect.  In Britain 
and many other countries in the late twentieth century, we have seen large increases 
in the legal penalties for drug possession which did not apparently prevent large 
increases in rates of drug use.  This may be due, as noted above, to the small 
proportion of drug users who are detected and punished.  
Punishment for drug offences
Even though the proportion is small, considerable police time is spent on dealing 
with drug offenders, and especially those apprehended in possession of cannabis.  
Cannabis was the drug involved in 71% of drug cases dealt with by caution or 
conviction in Britain in 2003 (Eaton et al.  2005).  Before the reclassification of 
cannabis, it had been estimated that a police officer spent an average of five 
hours in dealing with each cannabis offence (May et al. 2002).  This report also 
commented on the negative effects on confidence in the police among those who 
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had been dealt with for cannabis possession and noted the wide disparity between 
police force areas in the proportions of these offences that were dealt with by 
caution and by the various available sentences.  This suggested that the harshness 
of punishment of cannabis users depended on where they live, as well as on their 
record and the seriousness of their offence.
In 2001, the so-called Brixton experiment tested the policy of saving police time by 
instructing officers not to arrest people they found in possession of cannabis, but 
to confiscate the drug and issue a warning.  An evaluation of this experiment found 
that it was successful in freeing up police time, some of which was spent on an 
increased concentration on Class A drugs (PRS 2002).  The policy was controversial, 
but was apparently popular, though not universally, with the local community.  In 
an opinion poll, only 8% of Lambeth residents sampled disapproved of the scheme 
(Ipsos MORI 2002).  The government cited this experiment in justifying the decision 
to reclassify cannabis to Class C.  This was again controversial, and the subsequent 
Home Secretary, Charles Clarke, set up a review of the policy before the 2005 
general election.  In January 2006, he followed the advice of the ACMD and the 
Association of Chief Police Officers and kept cannabis in Class C.
The current position in England and Wales is that an adult will not usually be 
arrested for possession of small amounts of cannabis, unless there are aggravating 
circumstances (ACPO 2007).  People under 18 are still arrested, and the presumption 
of arrest remains for cannabis offenders in Scotland.  The Home Office (2005b) has 
reported that reclassification led to a third fewer arrests for cannabis possession 
in the first year, with an associated saving of 199,000 hours of police time.  For 
all drug offences, the number of people arrested in England and Wales fell from 
97,800 in 2003/4 to 72,700 people in 2004/5 (Ayres and Murray 2005).  However, 
in 2004 there were still 27,698 convictions for drug possession in a court in England 
and Wales (Mwenda 2005).  All those convicted or cautioned received a criminal 
record, with uncertain but potentially damaging effects on future employment 
prospects (Fletcher 2001).  Over 20,000 verdicts for possession led to some form of 
punishment and over 1,000 led to immediate imprisonment (Home Office 2005a).5 
The majority of these prison sentences were for Class A drugs, but 174 were for 
possession of Class B drugs, and 82 for Class C drugs.
Including sentences for trafficking and supply, 7,981 prison sentences were given 
for drug law offences in England and Wales in 2004 (Nicholas et al.  2005).  Of the 
people sentenced to prison, 30% were sentenced for possession, 58% for dealing, 
9% for trafficking and 2% for production of drugs.  Of the 6,300 people who 
admitted or were found guilty of dealing, 61% were imprisoned, compared to 5% of 
the 71,250 offenders on charges of possession (Mwenda 2005).  The costs to these 
individuals and their families, in terms of loss of liberty, loss of earnings, damage 
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to relationships and family break-up are important, though not estimable.  We can 
estimate the cost to the taxpayer.  At 2001/2 prices6 and assuming that prisoners 
serve half their sentences, but with no overcrowding, the estimated cost of these 
prison sentences exceeded £453 million.  
Since 1994, both the number of people sentenced and the average length of 
sentences for drug offences have been rising.7  This means that the number of 
prison years given in sentences has been rising faster still, and it is rising even 
faster for drug offences.  Figure 4.3 shows that the number of prison years given 
in sentences for drug offences rose substantially in the eleven years from 1994.  
Between 1998 and 2005, this number increased by 22%.  The number of people 
imprisoned for possession in England and Wales peaked in 1998, but was still 
8% higher in 2004 than in 1994.  There were increases between 1994 and 2004 in 
both the absolute numbers of people imprisoned and in the proportion of known 
offenders who are imprisoned for each of the categories of drug offence.  The 
proportion of imprisoned offenders who are given longer prison sentences has 
also been increasing for all offences (ibid.: supplementary tables).  The use of 
imprisonment has grown especially rapidly for drug dealers and distributors, but 
imprisonment was also used more for possession offences in 2004 than it was 
in the mid 1990s.  The number of people sent to prison for drug law offences has 
also increased in Scotland, by approximately 26% between 1995/6 and 2004/5 
(Scottish Executive 2006a).  These increases will in all likelihood have contributed 
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Enforcement of the MDA therefore takes a very large and increasing proportion of 
the total public expenditure on drug problems.  
International evidence
Internationally, the criminal penalties faced by drug users vary considerably.  Many 
states in the USA continue to enforce a policy of strict punishment for possession 
and distribution of even small amounts.  However, eleven US states, as well as four 
Australian jurisdictions and a few European countries, notably the Netherlands 
and Portugal, have effectively decriminalised the possession of small amounts of 
cannabis.  This has been done by replacing criminal with civil penalties, or, in the 
case of the Netherlands, by introducing a formal written policy for the expedient 
tolerance of distribution and possession of limited amounts of the drug (which 
remains formally prohibited).  
There were no greater increases in cannabis use or favourable attitudes towards 
the drug in the US states that decriminalised its possession than were experienced 
in the states that did not (Single et al. 2000).  More recent research comparing 
rates of cannabis/marijuana use in San Francisco and Amsterdam, two liberal 
cities with very different approaches to prohibition, found similar rates of use, 
although slightly higher in San Francisco (Reinarman et al. 2004).  The data from 
the Netherlands suggests that the de-penalisation of cannabis use does not of itself 
lead to increased use, although the commercial promotion of the drug may have had 
such an effect (MacCoun and Reuter 2001).  Recent research (Pacula et al.  2004) 
shows that decriminalisation in the US has made only a limited difference, in part 
because criminal penalties remain for those who are caught using the drug even 
where they have been eliminated for possession.
In Portugal, the decriminalisation of small amounts of all types of drugs in 2001 has 
apparently been followed by an increase in non-opiate drug-related deaths (from 
19 in 1999 to 54 in 2003).  Meanwhile, opiate drug-related deaths fell substantially 
(from 350 to 98).  It is difficult to attribute causality in these trends to the change in 
drug laws.  For example, the fall in opiate-related deaths has been attributed to a 
rapid increase in the capacity of opiate substitution treatment, and not to drug laws 
(Tavares et al.  2005).
The difficulty of attributing changes in drug use to legislation is also suggested 
by the case of Italy.  Until 1975, drug possession was illegal and repressed.  That 
year, possession of small amounts of drugs for personal use was decriminalised, 
while sanctions for trafficking were increased.  In 1990, this law was repealed, 
and sanctions were reintroduced for personal possession.  In 1993, a popular 
referendum took policy back to one of tolerance of possession for personal use, 
although administrative measures, such as suspension of driving licences and 
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passports, continued to be used.  Throughout all these changes in legislation, use 
of drugs tended to increase, with no apparent effect from either legal tolerance or 
repression (Solivetti 2001).  
Overall, the international evidence suggests that drug laws do not have direct 
effects on the prevalence of drug use.  However, enforcement of drug laws may have 
effects on other drug-related harms.  For example, targeting drug users and dealers 
for arrest may encourage them to adopt practices that are dangerous for their 
health.  A comparative study in New York and Rotterdam showed that the tougher 
US approach damaged the possibilities of sharing health information through 
networks of users and dealers (Grund et al. 1992).  A recent US study has shown 
that those cities with a tougher approach to enforcement do not have lower levels 
of injecting drug use, but do have higher levels of HIV infection among injectors 
(Friedman et al. 2006).
Addressing drug markets
A review of the international literature in this field has recently been carried out by 
the Australian Drug Policy Modeling Project (Mazerolle et al. 2005).  The available 
evidence suggests that enforcement of drug laws can have effects in reducing the 
harm associated with drug markets, but only when this is done in partnership with 
other agencies.  Police efforts to eradicate drug markets by arresting users and 
dealers do not usually lead to sustained reductions in drug-related harm.  
In several US projects reviewed by Mazerolle et al. partnerships between police, 
local authorities, housing departments and family services did achieve such 
reductions.  The partnerships have shut down locations where drugs were being 
used, forced private landlords to fulfil their responsibilities, used nuisance 
abatement orders and provided support to local families.  The benefits produced 
have included reductions in drug sales and related crime, and improved community 
relations.  However, there is also evidence of displacement effects in such 
initiatives.  And the failure of some programmes, such as those in the US ‘Fighting 
back’ evaluation, to reduce drug use or related harms (Saxe et al.  2006) shows 
that success in multi-agency and community-based programmes is still difficult to 
achieve
As seen in Mazerolle et al.’s review, collaborative operations against drug markets 
may have other consequences than reducing drug use and crime.  Drug dealing in 
deprived communities hinders their regeneration, saps community confidence and 
damages the reputation of the area (Lupton et al. 2002).  Local residents may be 
reassured by seeing the police take visible action against drug dealers and this may 
have benefits in improving the community’s quality of life.  Police tactics may affect 
the achievement of these secondary benefits.  Harms to communities seem to be 
The impact of current drug policies
61
less severe where drug selling is hidden rather than visible (ibid.).  Actions against 
visible drug markets may boost public perceptions of the safety of the community 
and of the responsiveness of the local authorities.  
However, there is little evidence of reductions in drug use from targeting distributors 
and retailers of illicit drugs for arrest.  The available studies, while not generally 
of very high methodological quality, suggest that crackdowns tend to lead to 
changes rather than reductions in drug selling and using.  These activities tend 
to be displaced to areas outside the crackdown area and move back in once the 
operation is over.  Even where police efforts have led to numerous arrests of dealers 
and seizures of large quantities of drugs, it has been difficult to discern sustainable 
impacts in reducing drug use or other crimes.  One example is Operation Crackdown, 
which was launched in London in November 2000, and is claimed by the government 
as another of the drug strategy’s ‘key achievements’ (Home Office 2005d).  In the 
first 14 days, drugs with a street value of £1.5 million were seized and over 240 
people arrested.  However, interviews with drug users found that there were few 
changes in drug availability, price or use (Best et al. 2001).  
Another example is provided by the Derbyshire Drug Market Project.  This arrested 
drug dealers and aimed to get users to enter treatment by creating a shortage of 
drugs and doing outreach work.  However, the project did not create a shortage 
of drugs.  There was no effect on overdoses or crime rates.  The drug market was 
apparently temporarily shut down in two towns, to the appreciation of the local 
community, but users were able quickly to find alternative suppliers.  Fewer users 
than anticipated entered treatment, partly due to mistrust of treatment services 
working with the police, and retention rates were poor for those who did enter 
treatment (Parker and Egginton undated, Parker 2004).  
Law enforcement is not the only way to tackle the harms associated with drug 
markets.  Other countries have attempted to limit these harms by relaxing 
the enforcement of prohibition of some drugs.  For example, the Netherlands’ 
expedient policy on the distribution of cannabis has been justified by its effects 
in separating the markets for cannabis and more dangerous drugs.  Supporters of 
this policy point to the rise in the average age of Dutch heroin users as indicating 
success in preventing young cannabis users from progressing to other drugs.8  
Some Dutch cities also have experience of informal cooperation with dealers of 
heroin and cocaine in order to minimise the health and public nuisance impacts of 
the drug market.  For example, the Rotterdam ‘Safe and clean’ strategy involved 
communicating with dealers and tolerating some sites where drugs, including 
heroin and crack, were known to be consumed.  This aimed to avoid pushing drug 
users into the unsafe conditions of the street and causing nuisance to residents 
(Van De Mheen and Gruter 2004).  
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Another approach is to reduce incentives to drug use and dealing by increasing 
opportunities for unemployed young men who are most at risk of getting involved 
in the trade.  A US study found that even modest improvements in the accessibility 
of jobs for young men can have significant effects in reducing drug dealing in poor 
neighbourhoods (Ihlanfeldt 2007).  
It seems it is very difficult to produce changes in drug use or related crime patterns 
by disrupting the drug market, although there may be other benefits that arise 
from targeting drug dealers.  These benefits seem most likely to arise where 
proactive partnerships target the range of drug-related harms, rather than confining 
themselves to crackdowns against drug dealers.  
Border interdiction
Customs and Excise (now part of HM Revenue and Customs) has historically been an 
important participant in drug policy.  It accounts for most major seizures at the ports 
and airports of the UK and for a large share of the total quantity seized.  In addition, 
drugs liaison officers, recently transferred to the Serious and Organised Crime 
Agency, work in countries of drug production and transit to assist these countries 
to reduce their exports of drugs to the UK.  The market share of drugs seized is 
estimated to be about 12% for heroin, 9% for cocaine and 25% for cannabis (Pudney 
et al. 2006).
Most of the price of a drug is accounted for by transactions after it enters the UK.  
For example, the effective price of a kilogram of heroin increases by a factor of 20 
in its journey from the fields of Afghanistan to Heathrow airport or Felixstowe port.  
It then increases to approximately 100–200 times the original price in its passage 
from the drug importer to the consumer (as estimated by Boyum and Reuter in 
2005).  The latest available data shows even greater increases between farm gate 
and street prices.  In 2005, the farm gate price of opium in Afghanistan was £51 per 
kilogram (UNODC 2006b).  Assuming it takes 4 kg of opium to make 1 kg of 40% 
pure street heroin, the effective farm gate price of a kilogram of heroin was £204.  
By the time this heroin reached British streets, it was selling for about £54,000  
per kg (SOCA 2006).  
The farm gate price of the drug is such a small element of the street price that major 
changes in production and seizure levels are likely to have only minor effects on the 
price to drug users.  Increases in smuggling costs can be passed on with minimal 
consequences for consumption.  The Prime Minister’s Strategy Unit (PMSU 2003) 
asserted (without much of a transparent analytic foundation) that even a seizure 
rate of 60% would not lead to much reduction in the amount of drugs imported,9 
as the financial incentives for importers are so high.  Some research has suggested 
that demand for drugs is elastic to the retail price (i.e. total expenditure falls as the 
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price increases) (Caulkins 2004).  This idea motivates the use of border interdiction 
to restrict supply, increase price and therefore reduce drug use.  However, it is very 
difficult indeed to achieve large enough reductions in supply to increase the retail 
price and so affect drug use.  
Despite the known difficulties of affecting drug use through restricting supply, 
the 2002 drug strategy emphasised the importance of preventing the drugs 
from entering the UK.  This was to be achieved through greater inter-agency and 
international co-operation and by increasing prison sentences for drug traffickers.
Figure 4.4 shows that there has been a dramatic increase in recent years in the 
amount of drugs seized in England and Wales, but with some large fluctuations 
caused by a small number of large seizures.  These seizures have been claimed as 
a ‘key achievement’ in a brochure on the impact of the drug strategy (Home Office 
2005d).  However, the Prime Minister’s Strategy Unit report concluded ‘drug seizures 
in themselves are having little or no impact on reducing harms’.  This is because the 
level of seizures that would affect supply is ‘not achievable’ (PMSU 2003).  
Several international studies of the effect of drug seizures have shown that they 
usually do not affect rates of drug use (Mazerolle et al. 2005).10  One contrasting 
example is the Australian heroin drought (Degenhardt et al.  2006).  A combination 
of police and customs operations and changes in patterns of production and 
distribution in Southeast Asia led to a shortage of heroin to Australian users in 
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reduction in opiate overdoses and a reduction in opiate-related deaths from 1,116 in 
1999 to 386 in 2001, showing that there are important potential benefits in limiting 
drug supply.  There were also reductions in notifications of hepatitis C infections and 
in the operations of street drug markets.  But there were also negative outcomes, 
such as a reported increase in mental disorders due to use of stimulants, including 
methamphetamine, and problems related to the injection of amphetamines and 
cocaine.  There appears to have been little long-term effect on crime, although there 
were short-term increases in both property and violent crime at the start of the 
drought (Bush et al. 2004).  
Australia had some important features associated with producing the shortage and 
mediating its effects.  These include geographical isolation, a relatively small heroin 
market that had been flooded in the late 1990s, a limited cocaine market and a 
well-developed treatment system.  The UK has not been able to replicate the heroin 
shortage or its effects through drug seizure.  The street price of heroin fell from £70 
to £54 per gram between 2000 and 2005 (SOCA 2006) and most other drug prices 
are also falling (see Figure 4.5).
Controlling production
It is estimated that about 90% of the UK’s identified heroin supply comes from 
poppies grown in Afghanistan (SOCA 2006).  The British government spent over 
£2.5 million on crop eradication in Afghanistan in 2004/5 and has also supplied 
and maintained helicopters for the Pakistani military (Rammell 2005).  The Ministry 
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cost of military operations in Afghanistan over the five years from 2005/6 (House 
of Commons Defence Committee 2006).  Current operations by British troops are 
assisting the Afghanistan government’s programme of drug control.  They have 
encountered stiff opposition, for example, in the opium producing Sangin valley.  
Between November 2001 and February 2007, 50 British soldiers were killed in 
Afghanistan, with increasing frequency after their deployment in Helmand province 
(historically the principal producing region) in 2006.  Despite these efforts, poppy 
cultivation reached record levels this year (UNODC 2006), as predicted by the 
UNODC and the British government earlier in the year (Howells 2006).11  
The available evidence on crop eradication suggests that we should not be 
surprised by the apparent lack of impact of current efforts.  Successes in reducing 
supply by controlling production have been rare.  Two examples are the Turkish 
opium ban in the early 1970s and the Mexican government’s programme of opium 
eradication later that decade (Boyum and Reuter 2005).  In both cases, supply 
of heroin to the United States was substantially reduced.  However, within four 
years new sources were found to meet demand.  And the circumstances of these 
successes are unlikely to be repeated in Afghanistan.  Both Mexico and Turkey were 
under the control of strong governments and had other major crops and industries 
to which farmers could turn.  Thus the governments were able to effect substantial 
reductions in opium production.  
In Afghanistan, as in Colombia and Myanmar, the government is not in full control of 
the crop growing regions, and those regional populations have few other livelihoods 
to turn to.  The current opium eradication efforts in Myanmar are likely to lead to 
widespread destitution (Jelsma and Kramer 2005), an outcome that Afghani farmers 
are apparently fighting alongside the Taliban to avoid.  The President of Afghanistan 
has expressed reservations on the repressive tactics used by coalition forces in 
seeking out opium stocks, and regional leaders have warned that, unless enough 
aid reaches rural areas, farmers are likely to see opium as their only way of making 
a living.  Current US moves towards the spraying of poppy fields with weed killer 
are not likely to lead to increased security or to sustained reductions in opium 
production (Jelsma et al. 2006).  In this context, the current targets of 70% reduction 
in Afghani opium production by 2008 and total elimination by 2013 have little 
operational meaning and are unlikely to be achieved.  
Crop eradication also imposes harms on the populations of drug producing 
countries.  It may leave communities without any source of income.  It can involve 
serious allegations of the abuse of the human rights of local populations.  And it can 
damage the environment through the use of poisonous chemicals and by driving 
cultivation away from farms into fragile and precious areas of biodiversity (Jelsma 
and Kramer 2005, Vargas 2005).  
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The available evidence suggests that drug law enforcement has little effect on the 
overall level of drug use.  However, law enforcement agencies can have significant 
impacts on the types and levels of harms that are associated with drugs.  For 
example, improved targeting of police resources on the most harmful traffickers 
and dealers (e.g.  the most violent, or those importing drugs that are not yet 
widespread12), may cost more in the short run than targeting low level markets, but 
may be associated with greater reductions in harms and costs (Caulkins 2004).  
Prevention
As one of the main indicators used to assess drug policy is its effect on the rate of 
drug use among young people, it is important to examine the efforts that are taken 
to reduce this rate.  Prevention is cited as the main policy area aiming to reduce 
drug initiation and continued use.  The policy is predicated on the assumption that 
prevention efforts reduce drug use, but there is, as yet, no clear evidence showing 
that prevention has had this effect in the UK.
There are three main strategies for drug prevention.  The first uses mass media 
campaigns to inform and warn the public of the dangers of drug use.  The second 
involves educating children at school about drugs.  The third consists of efforts to 
raise awareness and change attitudes in targeted groups, such as vulnerable and 
disadvantaged young people.  The first mass media drug prevention initiative in 
Britain was the Heroin Screws You Up campaign of 1985–86.  More recently, there 
has been the Apple campaign in Northern Ireland in 1997/8, the Know the Score 
heroin campaign in Scotland in 2005 and the Frank campaign in England.  The Frank 
campaign makes particular use of the Internet to communicate with young people.  
The government has reported that the website receives over 15,000 hits per day, and 
that £9 million was spent on the campaign between 2003 and 2006 (Home Office 
2006a).  
These campaigns have been supplemented by increases in the coverage of school 
drug education programmes.  The government has for some time expected schools 
to provide drug education to all pupils in all four countries of the UK.  Guidance on 
drug education advocates a whole school approach that includes the full range of 
psychoactive substances, including alcohol and tobacco, and incorporates drug 
education into other aspects of the curriculum.  In England during key stage 2 (ages 
7–11), children should be taught about the effects of the various drugs and how 
to make informed decisions about their health.  This work is then built on through 
key stages 3 and 4 (ages 11–16).  The guidance advocates use of evidence-based 
programmes that are interactive, skills-based and provide knowledge on the actual 
rates of drug use among their peer group (which children often overestimate) (DfES 
2004).  
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The schools inspectorate in England has reported significant improvements in 
coverage and quality of drug education.  Only two out of five primary schools 
were providing drug education in 1997.  By 2004, this had increased to four out of 
five.  However, the inspectorate warned that the lack of evidence on effectiveness 
makes it difficult to predict impact on drug use (Ofsted 2005).  In order to develop 
this evidence base, the government has also funded the Blueprint programme.  
This involves several components, including specialist education in schools and 
information for parents, coordination with local health policy and work with the 
media.  Its evaluation is due in 2007.  
The government has also targeted awareness and information campaigns at groups 
of young people who are most at risk of drug misuse, including young offenders, 
those in local authority care, school truants and excludees, children of problematic 
drug users, homeless young people and those exploited by prostitution.  The major 
targeted drug prevention initiative is the Positive Futures programme, which aims to 
reduce drug use through involving young people in sporting and creative activities.  
Over 100,000 people have taken part in this programme since 2002.  There is a high 
level of confidence by agencies working with the programme of its effect in reducing 
drug use, but no evaluation of its actual impact (Home Office 2006b).
There are two main limits to the likely return on investment in all three prevention 
strategies.  The first is the research evidence suggesting that prevention rarely leads 
to reduced drug use.  The second is that, even if it does reduce some drug use, this 
is unlikely to lead to major reductions in drug problems.
Mass media campaigns have rarely been rigorously evaluated in the UK.  The 
Scottish Know the Score campaign of 2005 was evaluated, but only in terms of 
the impact it had on attitudes towards heroin use, and not on actual use of heroin.  
There was no consistent pattern in these attitudes before and after the campaign 
(Scottish Executive Social Research 2006), a finding that challenges any assumption 
that the campaign will have reduced heroin use.  A study of the Northern Irish Apple 
campaign did find positive changes in attitudes to drugs (Ives and Wyvill 2000), 
but the campaign did not prevent a sharp rise in drug use in Northern Ireland from 
occurring.  The $1.2 billion dollar National Youth Anti-Drug Media Campaign in the 
USA was evaluated in terms of its effects on actual drug use.  None were found, 
apart from a small association between exposure to the campaign and increased 
initiation of marijuana use.  The US Government Accountability Office reviewed and 
endorsed this evaluation and recommended that the budget for the campaign be cut 
(GAO 2006).
Even though the government seems to have learnt some of the lessons of failed 
school-based drug education programmes, such as the internationally widespread 
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Drug Abuse Resistance Education programme (GAO 2003), there is still little 
acknowledgement that most drug prevention education has had no impact on rates 
of drug use.  These failures have been explained with reference to the contextual 
and familial effects on drug use, which schools can do little about, and the low 
dosage of drug education that schools can typically provide (Hawthorne 2001).  
There are some examples of drug education initiatives that demonstrated effect in 
reducing drug use rates (McGrath et al. 2006).  The impact of even these effective 
programmes tends to be small (Gottfredson et al. 2000) and they tend to share 
characteristics (including high intensity and programme integrity, encouraged by the 
presence of evaluators) that are difficult to spread across an entire school system 
(see Gottfredson and Gottfredson 2002).  Current evidence on drug prevention 
efforts suggests how difficult it is to apply evidence on best practice to the reality of 
school life.  For example, preliminary findings from a survey of Scottish schools are 
that teachers were using out-of-date and ineffective materials, with little training, 
and that pupils found drug education to be ‘uninspiring and unrelated to their own 
experience’  (ACMD 2006).  
Partly because of the small effects of even the most successful drug prevention 
programmes, they are unlikely to have major effects on overall rates of drug use.  
The positive effects of many such programmes are short-lived and may not persist 
beyond a few months.  If they do, there may be knock-on effects in preventing the 
spread of drug use through social networks, meaning that successful prevention 
with one individual may reduce drug use among his or her peers in future.  Even 
taking such effects into account it has been estimated (with a great deal of 
acknowledged uncertainty) that, if the USA were to implement fully the most 
effective known programmes, this would lead to a reduction of between 2% and 
11% in the future consumption of cocaine (Caulkins et al. 1999).  Relatively small 
changes such as this, which apply to the full population of drug users, are unlikely 
to have major impacts on problematic use, which affects a small minority of illicit 
drug users but accounts for the vast majority of drug-related harm.
A more recent entry onto the agenda of drug prevention in Britain is the issue of 
random drug testing in schools.  This has been used at only one state school so far, 
the Abbey School in Faversham in Kent, with funding from the News of the World 
for over 500 tests in the two academic years 2004/5 and 2005/6.  There was only 
one positive test (James 2006) and we understand the testing programme has now 
stopped.  However, two successive education ministers have signalled their support 
for random drug testing in schools.  
Drug testing has already been introduced in many US schools, and the results of 
research so far do not support its introduction in the UK.  Some small, uncontrolled 
studies have shown that drug testing reduced drug use.  However, the largest study 
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so far, involving 94,000 American pupils, with methodologically sophisticated 
controls for other influences, found that there was no significant difference in rates 
of drug use between schools that did or did not operate drug testing, including 
random drug testing programmes.  Rates of marijuana use were slightly lower in 
random drug testing schools, while rates of use of other drugs (including cocaine) 
were slightly higher (Yamaguchi et al. 2003).  It has often been argued that drug 
testing provides incentives to switch from cannabis to more dangerous drugs that 
are less easily detectable.  The Yamaguchi study suggests that, if drug testing in 
schools does have any effect, it is to encourage such switching.
There have also been suggestions that such programmes damage education by 
creating mistrust between teachers and pupils and by discouraging attendance 
at school by the pupils who are most vulnerable to exclusion and future drug 
problems.  Ofsted (2005) reported that most headteachers are against the idea of 
drug testing.  A review carried out for the Joseph Rowntree Foundation concluded, 
‘it would seem prudent for the government to advise caution rather than encourage 
experimentation with a costly and potentially damaging new approach to drug 
prevention’ (McKeganey 2005: 22).  The ACMD (2006) also recently declared its 
opposition to the use of random drug testing in schools.  
Overall, despite the government’s welcome emphasis on basing drug prevention 
on research evidence, it seems that there is still little reason to suppose that 
prevention will have substantial effects on initiation and prevalence of drug use 
among young people.  There is even less basis for confidence that it will reduce 
future levels of problematic drug use.
Treatment
The government has emphasised the role of treatment in reducing the prevalence 
of drug dependence and the high levels of harms that are associated with it.  There 
has since been a large expansion in the capacity of treatment services, and an 
increase in enrolment of approximately 110% since 1997/8.  This was a rational 
response to the large and increasing body of evidence that suggests that treatment 
of drug dependence is effective in reducing both the drug use and the offending of 
dependent drug users.  
The case for investment in treatment has recently been boosted by the National 
Institute for Health and Clinical Excellence’s rigorous studies of the available 
evidence and its resultant endorsement of a variety of treatment approaches, 
including maintenance prescriptions of methadone and buprenorphine, opiate 
detoxification, naltrexone and a range of psychosocial interventions, including 
cognitive behavioural treatment (NICE 2007a, 2007b, 2007c, 2007d).  Various other 
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treatment methods have also been shown to be effective in reducing illicit drug use.  
These include residential rehabilitation, motivational interviewing and counselling 
(Stevens et al. 2006).
The available evidence includes the English NTORS study, which showed significant 
reductions in crime and drug use for patients in four different drug treatment 
modalities: residential rehabilitation; in-patient drug dependency units; methadone 
maintenance; and methadone reduction programmes.  The cost–benefit ratio 
calculated for these outcomes ranges between £9.50 and £18 for each pound spent 
on treatment (depending on assumptions on crime costs)13 (Godfrey et al. 2004).  
NTORS had no control group, so it is hard to tell whether some of these benefits may 
have occurred in any case, as the respondents matured out of drug use and crime.  
But a recent analysis of criminal convictions of the sample showed that the pattern 
of convictions peaking before and then diminishing after treatment was present for 
all age groups (Gossop et al. 2006b).  This suggests that post-treatment reductions 
are not just a product of maturing out.14  More studies in a similar vein are now 
under way in England (the Drug Treatment Outcome Research Study) and Scotland 
(the Drug Outcome Research in Scotland Study), which will provide further useful 
information to inform UK drug policy.
So far, policy has focused on, first, getting more drug users in treatment and, 
more recently, improving the quality of treatment.  The mechanisms for expanding 
treatment engagement have been rapid growth in investment in drug treatment 
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into treatment.  As shown in Figure 4.6, the number in contact with structured 
treatment in England has more than doubled since 1998, from 85,000 in 1998/9 to 
181,390 in 2005/6.16  The government has already beaten its target to increase the 
numbers in treatment by 100% by 2008.  The target of 2.5 weeks for average waiting 
times for treatment has also been met.  It fell from 9.1 weeks in December 2001 
to 2.4 weeks in September 2005.  However, there is some scepticism among drug 
users and workers in the field on the validity of the data on waiting times, which 
are generated by agencies whose performance is monitored against this indicator.17  
There is also concern, as expressed by the Home Affairs Select Committee (2002), 
that not enough treatment is available for users of cocaine, especially crack.  
The dramatic increase in treatment capacity means that approximately 55% of 
the government’s estimated number of problematic drug users was in contact 
with structured treatment in 2005/6.  This is similar to the percentage of heroin 
users in the Netherlands in contact with treatment (Reuter and Pollack 2006).  By 
comparison, only 17% of those who were estimated as needing treatment received 
it in the USA in 2005 (SAMHSA 2006).  There has also been an expansion of drug 
treatment services in prisons.  Prisons hold high numbers of problematic drug users 
who can benefit from treatment.  The most recent survey of the psychiatric morbidity 
of prisoners found that 41% of sentenced male prisoners reported a measure of 
dependence in the year before their imprisonment (Singleton et al.  1997).  In 
1999, Counselling, Arrest, Referral, Advice and Throughcare (CARAT) teams were 
established in every prison in England and Wales.  These teams aim to identify, 
assess and treat those prisoners who have drug problems and to prepare continuity 
of care for when they are released.  They reported working on over 100,000 cases in 
the three years from 2002/3.  A significant minority of those people reported they 
had never received treatment for their drug problem (May 2005).  More recently, 
the NHS has taken over responsibility for health services in prison, including drug 
treatment.  By the end of March 2008 the Integrated Drug Treatment System is 
planned to be operational, providing a wider range of more intensive drug treatment 
services, including maintenance prescribing, to prisoners.  This represents a 
significant expansion in the provision of support, compared to the situation in 
1995 when the first prison drug strategy was launched (Duke 2003).  However, a 
qualitative evaluation of the work of CARAT teams has pointed out how difficult it 
still is to ensure continuity of care and effective multi-agency collaboration  (Harman 
and Paylor 2005).  Prison overcrowding makes this especially difficult, as it means 
that prisoners are often held in prisons far from their homes and are moved between 
prisons at short notice, causing interruption of treatment.  
Many offenders do not go to prison and prisons may not offer the most appropriate 
environment in which to provide effective and sustainable drug treatment.  A 
variety of other programmes have been used to encourage offenders to enter drug 
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treatment outside prison.  Chronologically, they include Schedule 1A6 Probation 
Orders, arrest referral schemes, the Drug Treatment and Testing Order (DTTO), drug 
testing on charge, the Drug Abstinence Requirement, Communities Against Drugs, 
the Drug Interventions Programme, restrictions on bail, conditional cautioning, the 
Drug Rehabilitation Requirement, the Prolific and Priority Offender Programme, 
testing on arrest and required assessments.  Scotland has also introduced (and 
kept) DTTOs and, through the Police, Public Order and Criminal Justice (Scotland) 
Act 2006, is also introducing mandatory drug testing on arrest.  Some of these 
programmes have been evaluated (see Box 4.1).  The target in England and Wales is 
to direct over 1,000 offenders into drug treatment per week by 2008 (this is targeted 
to represent 25% of treatment referrals).  The figure was 1,914 per month in June 
2005 (Home Office 2005d).  
Box 4.1  Evaluated criminal justice interventions
Drug Treatment and Testing Order
This order, introduced by the Crime and Disorder Act 1998 in both Scotland, and 
England and Wales, enabled the courts to order offenders to enter treatment or 
face alternative punishment (usually imprisonment) for their crime.  The early 
pilots were ‘hardly unequivocally successful’ (Turnbull et al. 2000: 87), but they 
were rolled out nationally nonetheless.  Subsequent research has suggested 
that offenders on DTTOs can do as well as those who enter drug treatment by 
other routes (McSweeney et al. 2006), although there have been consistent 
concerns about high rates of non-compliance and reconviction (Cuppleditch and 
Evans 2005).  The DTTO in Scotland was implemented more similarly to the US 
drug court system, and has shown higher completion and lower reconviction 
rates than its English counterpart (Eley et al. 2002, McIvor 2004).  The DTTO was 
replaced in England in 2005 by the similar, but more flexible, Drug Rehabilitation 
Requirement (DRR).
Drug Abstinence Order/Requirement
The Criminal Justice and Court Services Act 2000 introduced both the Drug 
Abstinence Order (DAO), a community sentence requiring a person to be tested 
for drug use, and the Drug Abstinence Requirement (DAR), a similar condition 
that could be attached to other community sentences.  In an evaluation of the 
DAO/DAR, there was a non-significant reduction in reported Class A drug use, 
compared to a matched comparison group, but a major increase in the numbers 
of offenders breached and sent to prison (Matrix MHA and NACRO 2003).  Both 
of these sentences were repealed in 2005, when the DRR became available to 
courts.
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The impact of drug treatment depends both on quantity and quality.  The NTORS 
study found that outcomes varied widely between treatment centres (although not 
between treatment modalities) (Best 2004).  A study in the North West of England 
found that the best-performing services were seven times more likely to retain clients 
than the worst (Millar et al. 2004).  In order to improve performance across the drug 
treatment field, the NTA launched a treatment effectiveness strategy in 2005, focusing 
on improving the commissioning and provision of services in order to enhance the 
client’s journey though treatment and beyond.  It has introduced targets for retention 
and has a specific programme to develop the skills of the rapidly expanding workforce.  
Implementing the strategy involves creating individualised packages of support for 
clients, including housing and employment services in order to achieve improvements 
in four domains (drug use, health, crime and social functioning) and to create better 
planned exit routes for those who can achieve abstinence.  In 2005/6, the NTA reported 
that 75% of those in treatment were retained for at least 12 weeks (Hayes 2006).  
Restriction on Bail
Introduced by the Criminal Justice Act 2003, this involves courts requiring 
defendants who test positive for Class A drugs to attend assessment and 
treatment as a condition of getting bail.  In the pilot phase, defendants were 
able to benefit from rapid access to treatment, but there was little evidence 
of reductions in crime.  The restrictions were used in addition to other bail 
conditions, rather than to reduce the use of custodial remands (Hucklesby et al.  
2005, 2007).
Drug Interventions Programme for Children and Young People 
This programme aims to encourage young offenders (aged 10–17) who are 
assessed as having problems with substance misuse to enter treatment by 
using arrest referral, drug testing on charge and drug treatment and testing 
requirements (DT(T)Rs).  It was piloted in ten areas from 2003.  The evaluation 
did not find that arrest referral or drug testing had increased rates of entry 
to treatment or had decreased drug use and offending.  There was a range of 
implementation problems and very few DT(T)Rs were made (Matrix Research and 
Consultancy and ICPR 2007).
Dedicated Drug Courts
These are courts that are specifically set up to deal with drug-involved offenders, 
who are sentenced to Drug Rehabilitation Requirements.  These courts have their 
cases reviewed by specially trained magistrates and judges, who are intended to 
provide continuity of contact with the offender through the sentencing and review 
process, following the US drug court model.  The pilot courts, in Leeds and West 
London, are currently being evaluated and the report is due in Spring 2007.
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There is potential to increase the coverage and effectiveness of treatment, as 
recommended by the National Institute for Health and Clinical Excellence (NICE 
2007a, 2007b, 2007c).  There is also evidence to support the introduction of new 
modes of treatment.  This is currently being done on a small scale.  The government 
is piloting heroin-assisted treatment (see below) in four sites.  Draft guidance (NICE 
2007d) includes evidence on positive results from pyschosocial treatments that are 
not widely available in the UK, including contingency management.  This involves 
providing vouchers, prizes or clinic privileges to reward good progress in treatment.  
It has been found to lead to longer periods of abstinence from illicit drug use among 
cocaine and heroin users in the USA (ibid.).  Another approach that is rare so far 
in the UK, but is spreading internationally, is multi-systemic family therapy for 
adolescents with drug use and other problems.  This has produced good results 
in many US studies, several international studies and is currently being piloted in 
London (Sheidow and Henggeler in press).  The similar, multi-dimensional therapy 
approach, which has also shown good results in the USA (Liddle et al. 2001), is now 
being piloted in Glasgow.  These multi-domain methods for working with young 
drug users respond to the current lack of evidence-based approaches for working 
with this group (Elliott et al.  2002).  There is also potential for developing new 
pharmacotherapies for cocaine users, but they have not yet got beyond showing 
promising results in small exploratory studies (Dackis et al. 2004).
It is in the expansion of drug treatment that UK drug policy sticks closest to its 
intention to make use of research evidence.  Internationally, there is much evidence 
to suggest that drug treatment is effective in reducing drug users’ health problems 
and the harms they cause to others (McLellan and Marsden 2003).  A review of 
research found robust evidence of cost-benefit from various types and settings of 
drug treatment (Belenko et al. 2005).  There were dangers attendant to the rapid 
expansion of drug treatment.  For example, the supply of qualified staff was small 
and it was possible that the marginal benefits of treating users would decline as 
more people entered treatment.  These threats have been acknowledged and at 
least partly dealt with.  For example, there has been significant effort put into 
workforce development and programmes have been focused on engaging the most 
problematic users in treatment services.
Where the policy goes beyond the available evidence is in some of the measures 
that have been used to encourage offenders into the system.  The ‘crime-driven’ 
nature of the expansion in treatment has not been without controversy.  It has been 
argued by some that it may have important detrimental effects on public health and 
the human rights of drug users by increasing the use of arrest and imprisonment, 
disrupting the treatment system for non-criminal drug users and taking attention 
away from the need to reduce bloodborne infections (Stimson 2000).  The evidence 
on the link between drug use and crime has been divorced from the social context 
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of both activities (Seddon 2005) and the focus has been on a direct causal link 
from drug use to crime.  Given that the link between drugs and crime is much more 
complicated than this, it is unlikely that drug treatment can achieve the reductions 
in overall crime rates that have been claimed for it.  This simplistic version of the 
drug–crime link has also been used to justify measures, such as compulsory testing, 
restrictions on bail and drug abstinence requirements, for which the evidence base 
remains very thin.  
The problem with some of these measures appears to be that they separate the 
requirement for abstinence from the provision of treatment.  Research in several 
countries, including England, has suggested that people who enter treatment when 
offered the choice between treatment and a different punishment for their crime 
can achieve reductions in drug use and offending that are at least as great as their 
counterparts who enter treatment without the involvement of the Criminal Justice 
System (Stevens et al. 2005, McSweeney et al. 2006).  People who enter such 
treatment do not necessarily experience their treatment as coerced as they retain an 
element of choice (Stevens et al. 2006a).  Some are able to use the treatment they 
are offered to escape lives of dependency and crime.  The research suggests that the 
treatment is important in enabling positive change.  Evidence on efforts to compel 
users into giving up drugs without treatment indicates that such initiatives are less 
likely to succeed (Stevens et al. 2005).  
The UK experience is not unique.  Drug dependence is seen as a chronic, relapsing 
condition.  Many people continue to use during and after treatment.  Even countries, 
such as the Netherlands, which have engaged high proportions of their heroin-
dependent populations in treatment, have not seen significant reductions in the 
size of this population (Reuter and Pollack 2006).  The expansion in drug treatment 
is likely to prove highly cost-effective in the reduction of problems at the individual 
level.  It may be playing an important role in the reported reductions in drug-related 
deaths.  With its proven effect in reducing the health and criminal problems of 
dependent drug users, it offers an effective response to those people who currently 
experience high levels of harm from their drug use.  However, given the wider socio-
economic, demographic and cultural effects on drug use and crime, it is unlikely that 
treatment will have dramatic effects in reducing overall rates of crime and drug use.  
Treatment does not prevent people initiating drug use and most problematic drug 
users go through several years of dependent use before entering treatment.  There 
is still a large group of dependent users who do not benefit from entry to treatment.  
It remains the approach to problematic drug use that has the greatest evidence for a 
significant return on public investment, but it is still likely to leave substantial drug-
related problems.
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Harm reduction
Another major element of efforts to reduce the adverse consequences of drug use 
is initiatives that seek to minimise the harm related to current drug use.  We have 
shown in Chapter 3 that the international experience suggests that the UK has 
invested wisely in harm reduction services such as needle exchange and opiate 
substitution treatment and so has limited deaths and costs from HIV/AIDS.  
Needle exchange and methadone maintenance treatment are among the most 
widely implemented harm reduction strategies, and there is strong evidence for 
their effectiveness in reducing drug-related deaths and transmission of infectious 
diseases (Wodak and Cooney 2004, Amato et al. 2005).  Methadone maintenance, 
which can be viewed both as treatment and as harm reduction (because it involves 
current use of a controlled drug) also has effects in reducing crime.  Other common 
approaches, such as the provision of information and the use of motivational 
interviewing to influence risk behaviours, have potential but less support from the 
little research that is available on them.  And there are new innovative programmes, 
including heroin-assisted treatment and drug consumption rooms, that are 
supported by available international evidence (Hunt 2003).
In order to increase the return on investment in harm reduction services, continued 
efforts will be needed to ensure broader coverage of services and that new users 
develop safer habits.  Economic modelling has been used to suggest that the 
cost-benefit of needle exchange can be maximised by making it available in all 
those communities that have high concentrations of injecting drug users (Harris 
2006).  There are plans to increase the coverage of methadone maintenance by, for 
example, ensuring continuity of prescription for those who enter and leave prisons 
(Marteau 2006).  In addition to the treatments endorsed by NICE, drug consumption 
rooms and heroin-assisted treatment also offer the promise of improved health and 
reduced cost (Home Affairs Select Committee 2002, Independent Working Group 
2006), although the evidence base for these approaches is, as yet, slimmer than 
those endorsed by NICE.  
Heroin-assisted treatment (HAT) differs from the existing system of prescribing 
heroin to small numbers of long-term dependent users.  It has been shown to lead 
to significant improvements in the health and social integration, and reductions 
in the offending, of patients in Switzerland and the Netherlands (van den Brink et 
al. 2003, Uchtenhagen et al. 1997).  In the Swiss programme, experienced heroin 
addicts who have failed in methadone treatment are admitted to programmes in 
which they receive heroin under professional supervision.  The clinics are open 
seven days a week and clients can attend up to three sessions each day.  
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In contrast to the earlier ‘British system’, the client is not limited in terms of the 
quantity of heroin to be injected.  The client can choose the amount that he or she 
wants to inject.  Over time those enrolled have usually reduced the quantity they 
consume daily.  Another important difference though is that the drug has to be 
consumed on the premises; there are no take-home privileges.  
The Swiss evaluation found that HAT led to large reductions in crime and health 
risk behaviours.  There seemed to be no diversion from the clinics to the black 
market (Uchtenhagen et al.  1997).  HAT has now become a routine part of the 
Swiss treatment system.  Approximately 1,500 patients are enrolled in HAT at any 
one time, about 10% of heroin addicts in treatment.  Even if HAT does not include a 
large proportion of those in treatment, they tend to be those who have particularly 
intractable dependencies, who have not responded to methadone treatment and 
who therefore risk causing a disproportionate amount of the harms related to 
heroin.
Perhaps the most important finding about heroin-assisted treatment emerged after 
the Swiss trials were concluded.  Over a longer period, it turned out that many of the 
patients exited HAT to some other form of treatment (Rehm et al. 2001) and many 
do move on to become abstinent after a period of stabilisation in heroin treatment 
(Guttinger et al. 2003).  This suggests that heroin maintenance is not a terminal 
but a transitional state, from which the addict comes to realise that their well-being 
depends not on having enough of the drug but on establishing a more positive life.  
The British government is funding a pilot study of HAT, which could become a very 
helpful addition to the range of programmes available for the most troubled and 
harm-causing heroin addicts.  
Drug consumption rooms (DCRs) can act as a recruiting point to help drug users 
enter treatment.  They provide safer places to use drugs, and are associated with 
reductions in overdoses and risky injection practices (Independent Working Group 
2006).  The government has rejected a parliamentary committee’s recommendation 
that safe injecting areas should be set up (Home Affairs Select Committee 2002) 
on various  grounds.  These include that they would create drug dens, would 
contravene UN conventions, would place additional burdens on NHS budgets, 
would create damaging confusion between HAT and DCRs, were not supported by 
European evaluations and would increase dealing, nuisance and acquisitive crime.  
The Independent Working Group (2006) examined all these concerns, and found 
that they were not supported by the available research and legal opinion.
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Conclusion
The British government has hardly neglected the problem of illicit drugs.  Over 
the last two decades it has used the major components of drug policy to, as the 
strategy title says, ‘tackle drug misuse’.  Enforcement has been used to prevent 
the distribution of drugs, prevention has attempted to reduce the rate of initiation 
into drug use, treatment has been expanded in order to deal with drug dependence 
and harm reduction efforts have aimed to reduce the adverse consequences of use.  
Each of these areas has seen substantial increases in funding in recent years and 
changes in strategy as well.
Enforcement has been the dominant programme in terms of expenditure, though 
it is hard to deduce that from the available budget documents.  If effective, 
enforcement should have raised prices and reduced availability.  For price there 
is direct evidence of declines rather than increases, at least over the last few 
years.  For availability there is no direct measure, but the continued high rates 
of use suggest that availability has not declined.  Perhaps, without the tough 
enforcement, prices would have been lower and availability even higher, but there is 
no evidentiary basis for that assertion and the US experience, at its most optimistic 
reading, shows quite modest effects of enforcement on price (Kuziemko and Levitt 
2004).
General increases in the use of imprisonment may raise the social and economic 
costs of drug policy, without providing commensurate benefits in reducing drug 
problems.  Efforts to eradicate crop production in politically unstable countries may 
have seriously detrimental impacts on British military forces and local populations, 
with little prospect of reducing the scale of domestic drug-related problems.  The 
increase in imprisonment of drug law offenders, and of people whose offending is 
associated with their drug use, has contributed to the current problem of severely 
overcrowded prisons.  And the costs of such imprisonment, to individuals, families 
and the taxpayer, have increased substantially in the last decade.  
Over the long term, prevention programmes have failed to achieve their primary 
aim of reducing initiation into drug use; youthful drug use has risen over most of 
the last decade and remains high.  Again, initiation rates might have been higher 
without these programmes but, given that the British rates are among the highest 
in the world, that is not very likely.  In view of the lack of evidence for effect of drug 
prevention programmes, it is doubtful that they have played a part in the apparent 
recent falls in the youthful use of cannabis.
Harm reduction is one area in which British efforts score well.  Proven harm 
reduction programmes are cost-effective and save lives (Wodak and Cooney 2004, 
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Amato et al.  2005).  This is an area where policy can have a significant impact in 
reducing the damage associated with drug use.  The majority of those who use 
needle exchange and opiate substitution continue to use drugs but do so less 
dangerously than before, with a consequent reduction in harms to themselves 
and to others (including crime for those in substitution treatment).  Given that the 
successes are now threatened by increases in drug-related diseases, consideration 
of the introduction of drug consumption rooms and the expansion of heroin-assisted 
treatment would appear appropriate.   
Treatment has strong and growing evidence that it is effective in meeting the needs 
of people who wish to reduce the damage caused by their drug dependence.  It 
appears to be highly cost-effective, largely through its impact on the criminality of 
patients.  The government has achieved its aim of a rapid expansion in the number 
of people in treatment, but there is still more to do in increasing the quality and 
effectiveness of treatment services.  NICE guidance now confirms that investment in 
drug treatment services will be cost-effective.  
The dominance of enforcement in the national drug control budget is also found in 
other countries, such as Australia, the Netherlands and Sweden, and above all the 
United States (Reuter and Pollack 2006).  In all cases, prosecution and incarceration 
are expensive; prevention and harm reduction are cheap.  Enforcement activities 
seem to have provided little benefit to count against their considerable costs.  
Prevention in practice also lacks evidence of cost-effectiveness, whereas some harm 
reduction efforts have proven that their benefits outweigh their costs, and others 
may provide similar returns on investment.  Most psychosocial treatments are 
moderately expensive, but appear to be cost-effective in reducing harms associated 
with drug use.  None of these strategies can eliminate the use of psychoactive 
drugs, but harm reduction and treatment have reduced the damages done to and by 
drug users.  
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CHAPTER 5
Policy and research issues
The principal purpose of this monograph is to provide readers with an 
understanding of the nature of Britain’s drug problems, how the government has 
responded to them and how effective its responses have been.  In this concluding 
section we summarise the analysis we have presented.  We present some 
conclusions on the state of drug policy research and we re-state the key overall 
conclusion of our analysis. 
The limits of policy
It is striking that, despite the longstanding political prominence of the drugs 
problem in the UK and despite relatively coherent strategies and substantial public 
investment, Britain, particularly England, has fared so poorly.  By measures of 
use and dependence rates, Britain is at the top of the European ladder.  This did 
not happen as the consequence of one short epidemic burst but is the result of a 
steady worsening in the last quarter of the twentieth century.   It is encouraging 
that the problem does not seem to have worsened since about 2000, but that is the 
strongest positive statement one can make confidently at present.
The most fundamental point to understand about drug policy is that there is little 
evidence that it can influence the number of drug users or the share of users who 
are dependent.  There is no research showing that any of the tougher enforcement, 
more prevention or increased treatment has substantially reduced the number of 
users or addicts in a nation.  There are numerous other cultural and social factors 
that appear to be much more important.  
What are the principal determinants of rates of drug use?  Surely fashion or 
popular culture has to be given considerable weight.  For example, in most nations 
throughout the Western world, from Australia to Finland, there was an upturn of 
about one-half in rates of cannabis use among 18-year-olds between approximately 
1992 and 1998 (MacCoun and Reuter 2001), though from very different base rates 
in the various countries.  Some of those nations had become tougher in their 
marijuana policies in that time (e.g. the US), most made no change and others 
became more tolerant (e.g.  Australia); the policy stance seemed to have no 
effect.  It is hard to identify which underlying cultural values drove these changes 
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simultaneously, but their breadth and consistency make it very likely that the 
increasingly globalised popular culture has a prominent role.  After about 1998, the 
growth stopped as abruptly as it started; again there is no policy intervention that 
one can turn to for an explanation.  Similarly the timing of epidemics of heroin use 
in different nations seems unrelated to government policy and appears to be driven 
instead by the confluence of broad demographic, social and economic changes.
This suggests that it is simply unreasonable to assess the government’s 
performance against measures of the prevalence of drug use, since no one can 
offer guidance as to what is likely to reduce prevalence.  Yet that is the indicator to 
which the public instinctively turns and which has been an important part of the 
British government’s own targets.1  There is a transparency to this measure and it 
connects to the principal drug concern of many people, particularly parents, which 
is the risk of children becoming involved with dangerous substances.  It is politically 
implausible to ignore population prevalence measures, but analysts should give 
more weight to other indicators, particularly related to harm such as drug-related 
crime and disease.  Though we offer many criticisms of the Drug Harm Index, this 
does represent an important step forward in focusing policy on the dimensions that 
the government can plausibly affect.  
More positively, this pessimistic view of policy also has a liberating effect.  The 
UK government, like many others, emphasises the importance of not sending ‘the 
wrong message’ about drugs.  As discussed above, that has been used to justify the 
current drug classification scheme, for example keeping ecstasy in Class A.  But if 
such classification and programmatic decisions have minimal consequence for drug 
use, then the ‘message’ argument fails and the government is permitted to make 
these decisions on grounds of justice and efficiency.  
Further, there are many unintended negative consequences of drug policy, 
particularly enforcement, that have been tolerated on the basis of the presumed 
necessity.  For example, the use of imprisonment for all categories of drug offences 
has increased in the last two decades.  The costs of this imprisonment are heavy 
for the taxpayer.  If as it appears, the majority of these offenders have been in 
prison for relatively lower level drug offences, then one might reasonably question 
whether average sentences of three years are effective.  The claim that increasingly 
tough enforcement sends a message that will reduce drug use does not appear 
to be supported by the evidence.  In particular, there has been a disproportionate 
impact on black people, who are more likely to be arrested and imprisoned for drug 
offences.  So, here again, policy needs to be re-considered.  
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Research needs 
If policy is to be improved, it should be based on more accurate and reliable 
information.  Here we offer a few observations about the state of drug policy 
research.
The first observation is simply that there is not much of it.  Furthermore, most of 
what there is come from North America.  In particular, there is a dearth of research 
on the consequences of drug enforcement efforts.  The Home Office is undertaking 
a variety of evaluations of drug enforcement in the United Kingdom but it will take 
a long time indeed at the current pace to provide policy makers with a reasonable 
evidence base for decisions.
More specifically, there is a need to assess the effects of the increasing amount of 
prison space devoted to drug offenders.  It could be argued that the UK is already 
very punitive to little benefit.  However, the available evidence is not strong and a 
UK-specific research base should be developed.
There is also a need to strengthen the Drug Harm Index.  Despite being a bold and 
laudable measure, the dominance of drug-related property crime in the current 
version does not have much authority.  A research programme to build both a better 
conceptual and empirical foundation for this Index would help with the future policy 
decisions.
At a more practical level, the transparency of drug budgeting needs to be improved.  
For the work in this review, we have had to develop our own very crude figures 
because it was impossible to determine the total from the various documents 
published.  Decisions about policy are largely decisions about expenditures; a 
capacity to at least roughly measure what is currently being spent is essential.  
Conclusion
Government policies have only limited impact on rates of drug use itself.  However 
policies are highly relevant because they can have significant impacts on the levels 
of drug-related harm.  There is now a great deal of international research showing 
significant reduction in lifetime drug use among drug users who receive treatment 
and substantial reductions in both crime and health risk behaviours, especially 
during the treatment episode.  Harm reduction initiatives, notably needle exchange 
and opiate substitution, reduce HIV risk behaviours – to the benefit of both 
individuals and society.  Some research shows that particular kinds of enforcement 
can reduce the openness and disorder around the distribution of drugs, an 
important source of harms.  And some research (although not from the UK) supports 
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the claim that well-designed and well-implemented prevention programmes can 
be cost-effective, even if they only moderately lower initiation rates.  The research 
suggests that the greatest reductions in drug-related harm have come from 
investment in treatment and harm reduction.  However, the bulk of expenditure on 
drug policy in the UK is still devoted to the enforcement of drug laws.
There is an urgent need to take more effective action to reduce Britain’s drug 
problems.  However, the current shortage of research means that policy makers 
have to operate partially blind when choosing effective measures to reduce the 
serious harms associated with the use of illicit drugs.  The UK has introduced 
evidence-based measures, notably the expansion of treatment and harm reduction, 
that have reduced the harms that would otherwise have occurred.  On the other 
hand, it operates measures, such as classifying drugs to deter use and increasing 
use of imprisonment, that have little or no support from the available research.  
Even if the government can do little to reduce overall rates of drug use, it could 
make better use of available evidence to choose policies that more effectively 
reduce drug-related death, crime, physical and mental health problems and other 
harms to the communities that currently suffer the consequences of drug use.




1  This report will cover the four countries of the United Kingdom.  Although policy 
in Northern Ireland, Scotland and Wales is influenced by decisions made in 
Westminster, it is not determined by them.  We will attempt to recognise some of 
the diversity, as well as similarities, between the various jurisdictions.  Northern 
Ireland receives little attention because few data are available.  Most indicators 
are available for England and Wales jointly, not separately.
2  From the 2000 British Crime Survey, it was estimated that over a third of violent 
offences involved an offender who was, in the view of the victim, under the 
influence of alcohol (Budd 2003).
3  Although Dorn and Jamieson (2000) argue that there is more room to reform 
drug policy within these conventions than is usually thought.
Chapter 2: Drug use in Britain
1  Some sense of the fragility of these estimates can be gained from the experience 
in the United States in 2002 when the flagship population survey made a number 
of methodological changes and produced higher estimates of the prevalence of 
use of cannabis and cocaine.  For example, respondents were offered financial 
incentives to participate and the name of the survey was changed from the 
rather off-putting National Household Survey on Drug Use to the more neutral 
National Survey on Drug Use and Health.  Not only did response rates rise by 
about 5 % (i.e. 80% of those approached to fill out the questionnaire agreed to 
do so, compared to 75% in 2001) but a higher percentage reported drug use; for 
example, the estimated number of new users of marijuana for the year 1995 rose 
from 2.5 million (using the 2001 survey) to 2.8 million using the 2002 survey.  
2  This estimate comes from recently improved methods that are not comparable 
to previous government estimates of the number of problematic drug users in 
England.
3  The low figure for those aged 16–19 is deceptive, since a substantial fraction 
have not yet begun their drug using careers.
4  Figures from 2001 onwards are not directly comparable with earlier years due 
to a change in the survey methods.  This is indicated by a broken rule between 
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2000 and 2001.
5  This is a surprising pattern.  The rise in the younger age groups should 
trickle through in the following years to the older age groups; we can offer no 
explanation for the observed pattern, which suggests sharp declines in initiation 
rates for 13- and 14-year-olds around 2003 as initiation rates for 11- and 12-year-
olds were rising.
6  Cannabis is used by more people but the harm they cause themselves and others 
individually and in total is much less.
7  The notification series certainly reflected changing medical behaviour; increased 
awareness of the problem of heroin addiction may have made it more likely that 
a heroin dependent patient would be reported by his or her doctor.  Also, as 
treatment became increasingly available from 1965 onwards this contributed to 
the increase in notifications.
8  For Scotland specific heroin overdose figures are available only from 1992 
onwards.
9  This refers to the number of seizures, a more stable indicator than the quantity 
seized, which can be driven by a small number of large seizures.  Quantity seized 
rose by even more between 1997 and 2000 but is unstable year to year.
10  Parker and Egginton (undated) report similar data for an unnamed city in 
Derbyshire.  Using self-reported year of initiation from a treatment sample in 
2004, they find evidence that the number of initiates rose fairly steadily (in 
proportionate terms) over the entire period 1980 to 2000.  In 1980 the number of 
initiates was less than 10; in 1990 it was 30 and by 2000 it was 100.
11  There are no long-term panel studies in the UK, but in the United States Hser et 
al.  (2001) reported on a 33-year follow-up of some early heroin users who had 
been in a civil commitment programme.  Nearly half of the original addicts – 284 
of 581 – had died by 1996–97; of the 242 still living who were interviewed, 40% 
reported heroin use in the past year, and 60% were unemployed.
12  Injected mixtures of heroin and cocaine.
13  This proportion will be affected by the availability of treatment for crack 
problems, which is less widely available than, for example, prescription of 
methadone for heroin users.
14  Comparable figures are not available for Northern Ireland, although it has been 
suggested that drug use among young people has risen from relatively low levels 
since the ceasefires following the 1998 Good Friday Agreement.
15  Only 4.7% of the British people in the QCT Europe study sample who reported 
heroin as their main problem drug also reported recent use of powder cocaine 
(unpublished data).
16  Caution should be applied to the interpretation of these figures, which come 
from surveys in different years, using different methods (e.g. telephone or 
in-person interviews) and some different age ranges (the ranges start at 14 
for Australia, 15 for Belgium, Greece, Spain, Ireland, Italy, Cyprus, Latvia, 
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Luxembourg, Northern Ireland, Netherlands, Portugal and Finland, 16 for 
Denmark, England and Wales and Poland, and 18 for USA, Czech Republic, 
Germany, Hungary, Malta, Slovakia and Sweden; they end between 59 and 64).  
Figures on heroin are not available from the EMCDDA for continental European 
countries.
17  Where the data is reported as a range, the average of the high and low end of the 
range has been used.  The United States government does not use the category 
of ‘problematic drug user’ but a standard estimate of the number of those who 
are dependent on cocaine, heroin and methamphetamine (which is a rough 
approximation to ‘problematic drug user’) for 2000 was about 4 million (Office of 
National Drug Control Policy 2004).  This would give a prevalence rate of about 
20 per thousand persons aged 15–64.
18  Again, extreme caution should be applied when comparing these statistics (in 
Figures 2.7 and 2.8) from different years and counting methods.
Chapter 3: Drug problems in Britain
1   Data from the psychiatric morbidity survey suggests that high earners are more 
likely to take drugs, especially if they also have a university degree (Stevens 
2003).
2   See the AMCD (2006) report, chapter 4, for a fuller discussion of the links 
between socio-economic deprivation, and other factors, in predicting drug use 
and dependency.
3  The same caution applies.  These figures refer to national studies where they are 
available, and regional studies if not. 
4   It has been suggested that those who inject crack are more likely to inject 
frequently, to share equipment and to risk the serious dangers of injecting in the 
groin.  Crack injection seems to be increasingly common among injecting drug 
users, with reported rates of 40% among IDUs in some English cities (Rhodes et 
al.  2006).
5   It should be noted that these figures represent notifications to the Health 
Protection Agency, and not the actual incidence of hepatitis C.  It is possible that 
the increases are due, in some part, to increased awareness and testing.
6   This is because only a small proportion of offences lead to arrest, and some 
people (especially previous arrestees and people whom the police recognise as 
drug users) may be more likely to be arrested for their crimes.  This means that 
arrestees provide an unrepresentative sample of the population of offenders.
7   A study by the Irish police found that drug using offenders were almost twice 




Chapter 4: The impact of current drug policies
1   This estimate is calculated by taking the Treasury’s report of public expenditure 
in each of the relevant categories, and multiplying it by the proportion of that 
category that is estimated to relate to offences under the MDA (these estimated 
proportions are listed in the ‘multiplier’ column of Table 4.1).  It does not include 
the costs of dealing with other offences that are committed by drug users.  The 
breakdown of expenditure on prison and offender programmes spent on prisons 
and probation is based on the proportions reported in the Home Office accounts 
for 2004/5.  The estimates rest on two fragile assumptions.  First, that the share 
of arrests for a particular offence is a good measure of the share of all resources 
(including prevention, investigation and management) that police allocate to 
that offence category.  Second, that drug arrests are as expensive as other kinds 
of arrests.   
2   For example, an examination of stop and search practices in two English towns 
found that the over-representation of black people compared to their proportions 
in the residential population was actually in line with the ethnic make-up of the 
population that was ‘available’ on the streets during the times when stop and 
searches were most likely to happen (Waddington et al. 2004).
3   The Committee stated that this would enable the classification of harmfulness 
to be more flexible to emerging evidence and noted police comments that the 
current classification system is not a major factor in police decisions.  It did not 
recommend an alternative method for determining penalties to be associated 
with drug offences.
4   The government itself was still using the 2002 forecasts rather than reports of 
actual expenditure in its 2005 report to the EMCDDA (Eaton et al. 2005).  
5   These figures only include cases where drug possession was the principal 
offence.  They exclude cases where the defendant was also convicted of a more 
serious offence.  They do not include cases of possession with intent to supply.  
Available figures for sentences in Scotland are not split by type of offence or 
class of drug.  In 2004/5, there were 973 custodial sentences, 1,028 community 
sentences, 4,633 fines and 820 cautions for drug law offences (Scottish 
Executive 2006a).
6   £36,535 per year per uncrowded prison place  (Councell and Olagundoye 2003).
7   The average length of sentence for drug offences in 2005 was 35.8 months, 
compared to 17.8 months for violence against the person, and 35 months for 
robbery (RDS NOMS 2007).
8   The average age of both drug treatment clients and people who die from drugs 
has risen significantly since the 1980s (Laar et al.  2004).
9   Globally, it is estimated that over one-third of cocaine is seized by some 
governments (UNODC 2005); this has not prevented declining prices for cocaine 
in most nations with large user populations.
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10  There is a suggested British example where seizure of drugs shifted, but did 
not reduce drug use.  The largest seizure of amphetamines in the UK, a result of 
Operation Pirate in 1998, led to a temporary shortage of amphetamine.  Cocaine 
and crack were becoming more available, and it has been argued that the seizure 
explains some of the move from amphetamine to cocaine that is seen in British 
Crime Survey figures (see Figures 2.1 and 2.2) (Atha 2006).
11  For a despairing and expert view of the prospects of eradicating Afghani opium 
production, see Mansfield and Pain (2006).
12  Methamphetamine provides an example of a potentially very harmful drug that is 
yet to establish a significant market share in the UK.
13  Ashton (1999) has criticised the use of marginal rather than full costs of 
treatment in this model.
14  It also confirms suggestions that offending tends to peak in the months before 
treatment entry, so that extrapolation from the NTORS sample’s offending in the 
three months previous to treatment entry to all problematic drug users over a 
year, as carried out by Godrey et al. (2002), is likely to provide an overestimate.
15  The monitoring system changed in 2003/4, although an estimate that is 
comparable to the current system has been provided for 1998/9.  Figures for 
1999/0 to 2002/3 are estimated here by applying the percentage increases in 
the old monitoring system to that estimate for 1998/9.
16  These figures refer to those who are assessed for entry to structured drug 
treatment.  Some of them may not make the transition into actually receiving 
treatment.
17  The system for generating data on waiting times is changing for the 2006/7 year.
Chapter 5: Policy and research issues
1   It is almost the exclusive indicator for the US National Drug Control Strategy.  
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